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Chapter 1 
 
 
Introduction 
 
 
The traditional role of RNA has been that it serves only as an intermediary between the DNA 
and encoded proteins. Non-coding RNAs (ncRNA) were thought to fulfill relatively generic 
functions in the process of decoding DNA and generating proteins, such as the roles played by 
ribosomal RNA (rRNA) and transfer RNA (tRNA) in mRNA translation. More recently, 
analyses comparing transcriptomes and genomes have established that in humans, approximately 
two-thirds of genomic DNA is pervasively transcribed, while less than 2-3% endodes proteins 
(Djebali et al. 2012). It is now increasingly evident that RNAs participate in a wide repertoire of 
biological functions, and as first predicted by Jacob and Monod 55 years ago (Jacob and Monod 
1961), play important roles in gene regulation, both in cis and in trans. The most recent addition 
to the expanding view of the role of RNA, both regulatory noncoding transcripts and transcripts 
encoding proteins, is the finding that RNA can be released into the extracellular milieu, 
suggesting a function beyond the cell of origin. 
 The first report of extracellular RNA (exRNA) was described in 2007 where mRNAs 
from mouse mast cells were transferred and translated into proteins in human recipient mast cells 
(Valadi et al. 2007). Since this initial discovery, various types of endogenous RNAs have been 
detected in the circulation, including messenger RNAs (mRNAs), microRNAs (miRNAs), and a 
variety of other non-coding RNAs (ncRNAs), such as circular RNAs (circRNAs), transfer RNAs 
(tRNAs), and ribosomal RNAs (rRNAs) (Valadi et al. 2007; Bellingham, Coleman, and Hill 
2012; Cha et al. 2015; Dou et al. 2016; Freedman et al. 2016). Although  a wide range of exRNA 
have been unambiguously identified, many of these sequences align to incomplete or 
unannotated regions (Vickers et al. 2015). Thus, it is likely that novel exRNAs are yet to be 
discovered. Nonetheless, specific RNAs are secreted into the extracellular milieu, and exhibit 
differences in processing and expression patterns dependent on their source (Bellingham, 
Coleman, and Hill 2012). RNA export appears to be evolutionarily well-conserved, as it has been 
documented in bacteria (Deng et al. 2015), plants (Brosnan and Voinnet 2011), fungi (Silva et al. 
2015), nematodes (Jose, Garcia, and Hunter 2011), flies (Lefebvre et al. 2016), and mammals 
(Valadi et al. 2007). Additionally, recent studies have found the presence of exogenous exRNAs 
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derived from diet or from the microbiome in human plasma and serum (H. Liang et al. 2015; 
Beatty et al. 2014), suggesting trans-species transfer of extracellular RNAs.  
 Because extracellular fluids display abundant ribonuclease (RNAse) activity, exRNAs 
must be protected from degradation.  ExRNAs in circulation are stabilized and protected from 
RNAses either in protein complexes (Arroyo et al. 2011; Andrey Turchinovich et al. 2011), lipid 
complexes (Vickers et al. 2011; Tabet et al. 2014; Wagner et al. 2013), or extracellular vesicles 
(EVs) (Bellingham, Coleman, and Hill 2012; Mittelbrunn et al. 2011; Skog et al. 2008). EVs 
represent a novel vehicle for intercellular communication in that they allow exchange of lipid, 
protein, RNA, and more recently, DNA cargo (Colombo, Raposo, and Théry 2014; Fischer et al. 
2016), and they are released by all cell types (Colombo, Raposo, and Théry 2014). Studies have 
also shown that cancer cells secrete many more EVs than healthy cells (reviewed in (D’Souza-
Schorey and Clancy 2012)). Thus, in the context of cancer, EVs can serve as vehicles for 
transport of exRNA from cancer cells to normal cells, both locally and systemically. From the 
perspective of a cancer cell, this potentially allows secretion of RNAs that could inhibit growth 
while simultaneously transferring oncogenic RNAs to healthy cells, contributing to overall 
cancer progression and drug resistance (Melo et al. 2014; Boelens et al. 2014). Interestingly, 
circulating RNAs encased in vesicles or protein complexesare often altered in cancer and bear 
tumor type-specific ‘signatures’, making them attractive candidates as clinical biomarkers for 
disease diagnosis and prognosis (Lawrie et al. 2008; Xi Chen et al. 2008; Mitchell et al. 2008; N. 
Kosaka et al. 2010).   
Although there is accumulating evidence to suggest that RNAs can function as 
extracellular signaling molecules, the origin, secretory mechanism(s), and physiological 
functions remain largely unknown. This review will focus on some of the different classes of 
exRNAs, particularly those found in EVs, and their roles in cancer. The mechanisms for exRNA 
loading into EVs and functional transfer into target cells will also be discussed. 
 
 
1.1 Composition of extracellular RNA 
 
 
The seminal finding that mRNAs and miRNAs can exist outside the cell and be 
transferred to recipient cells through extracellular vesicles (EVs) (Valadi et al. 2007) challenged 
the traditional view of RNA and led to the hypothesis that exRNAs can function in cell-to-cell 
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communication. Apart from coding RNA (mRNA), advances in next generation sequencing 
(NGS) technology have revealed a broad spectrum of ncRNAs in plasma, serum, biological 
fluids, and conditioned media from cell culture (Table 1). It is becoming more evident that the 
classes of RNAs enriched in EVs largely depend on the source cell. These profiles can be 
dynamically regulated in response to different stimuli and activation states (Montecalvo et al. 
2012; Y. Zhang et al. 2010).  
 
Table 1. Summary of different classes of exRNAs  
Name 
(abbreviation)
 
Size range 
(nt) 
Function(s) (reference) 
microRNA 
(miRNA, miR) 
19-22 Inhibits protein translation and/or facilitates degradation of mRNA 
(Eulalio, Tritschler, and Izaurralde 2009); activation of immune 
response (Fabbri et al. 2012) 
Small nucleolar 
RNA (snoRNA) 
60-300 Guides the methylation or pseudouridylation of rRNAs and other 
RNAs (Matera, Terns, and Terns 2007) 
Small nuclear 
RNA (snRNA) 
~150 Modulation of RNA polymerase II activity; splicing (Matera, Terns, 
and Terns 2007). 
Piwi-interacting 
RNA (piRNA) 
20-30 Chromatin modification and transposon silencing (Iwasaki, Siomi, and 
Siomi 2015) 
yRNA fragment 
(yRF) 
27-33 Cell proliferation (C. P. Christov, Trivier, and Krude 2008); apoptosis 
(Chakrabortty et al. 2015). 
tRNA-derived 
fragment (tRF) 
19-22 Translational repression, analogous to miRNAs (Haussecker et al. 
2010; Y. S. Lee et al. 2009) 
tRNA-derived 
half (tRH, 
tiRNA) 
30-40 Stress-induced translation repression (Yamasaki et al. 2009; P. Ivanov 
et al. 2011) 
Vault RNA 
fragments 
~23  Translation repression, analogous to miRNAs (Persson et al. 2009) 
Long ncRNA 
(lncRNA) 
>200  Chromatin remodeling (Meller, Joshi, and Deshpande 2015); 
translational regulation; mRNA stability (reviewed in (Fatica and 
Bozzoni 2014)) 
Circular RNA 
(circRNA) 
>80 nt miRNA sponges  (Hansen et al. 2013); transcriptional regulation (Z. Li 
et al. 2015) 
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mRNAs 
Intact mammalian mRNAs vary in length from 400 nucleotides (nt) up to >100,000 nt, 
with the average transcript being ~2,100 nt in size (Lander et al. 2001). Despite initial reports 
indicating the presence of mRNAs in EVs (Valadi et al. 2007), the majority of EV-associated 
RNAs fall within a size distribution of 25-700 nt from a variety of biofluids (Pegtel et al. 2010; 
Noerholm et al. 2012). Thus, it remains controversial whether these mRNAs are full-length or 
fragmented transcripts, though this may depend on the exact size and origin of the EV (see 
below). Nonetheless, transfer of mRNAs has been described for several tumor types, including 
colon and gastric cancer (Hong et al. 2009), glioblastoma (GBM) (Skog et al. 2008), leukemia 
(Milani et al. 2017), breast cancer (Conley et al. 2016), and prostate cancer (Lázaro-Ibáñez et al. 
2017).  The mRNAs appear to have tumor-specific signatures. In GBM cells, secreted EVs are 
enriched in mRNAs associated with cell proliferation, migration, angiogenesis, histone 
modification and immune repression (Skog et al. 2008). Additionally, mutant EGFRvIII 
transcripts can be detected in EVs isolated from the serum of GBM patients whose tumors 
expressed mutant EGFRvIII (Skog et al. 2008). Furthermore, colorectal cancer (CRC) cell EVs 
are enriched for mRNAs related to cell cycle pathways, specifically associated with M-phase 
activities (Hong et al. 2009). These M-phase-related mRNAs are differentially expressed across 
CRC patients, suggesting a potential role in tumor progression. Thus, tumor-specific RNAs in 
serum EVs could provide a cell-free ‘biopsy’ of the tumor cell to identify somatic mutations and 
changes in gene expression. 
In addition to coding sequences, other reports demonstrate that EV-associated mRNAs 
are largely enriched for 3’-UTR fragments (Batagov and Kurochkin 2013). Although the precise 
mechanisms for how 3’UTRs are selected for secretion are unknown, one possibility is that 
mRNAs undergo post-transcriptional cleavage to produce 3’UTR fragments, as reported by 
Mercer et al. (Mercer et al. 2011). Another possibility is that exosome-associated mRNAs 
undergo degradation after secretion via extracellular RNases. This seems unlikely, however, as 
we and others observe sequencing reads spanning both full-length transcripts as well as 
smaller/fragmented transcripts, suggesting that these fragments are generated within the cell 
before sorting into exosomes. 
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microRNAs (miRNAs) 
The most well studied exRNAs are miRNAs, one of the most abundant classes of small 
RNA found in plasma (Huang et al. 2013). miRNAs are single-stranded RNAs ~22 nt in length 
that bind to target mRNAs to inhibit their expression (For review, see (Bartel 2004)). With more 
than 24,000 identified vertebrate and invertebrate miRNAs (www.mirbase.org), they represent 
one of the largest gene families and are predicted to target 30-60% of protein coding genes 
(Griffiths-Jones et al. 2006; Bartel 2004). Since their initial discovery in C. elegans (R. C. Lee, 
Feinbaum, and Ambros 1993), miRNAs have proven fundamental to nearly every biological 
process. 
Canonical miRNA biogenesis occurs through a series of coordinated cropping and dicing 
steps to yield the ~22nt mature miRNA (Figure 2). This process begins with transcription of the 
miRNA-containing locus by RNA polymerase II (Pol II) in the nucleus to produce long, hairpin-
shaped transcripts that are subsequently processed to precursor-miRNAs (pre-miRNAs) by the 
microprocessor, which minimally contains the RNAse III enzyme Drosha in complex with the 
DiGeorge Critical Region 8 (DGCR8/Pasha) (Y. Lee et al. 2003; Gregory et al. 2004). Pre-
miRNAs are recognized by the nuclear export protein, Exportin-5, and are transported out of the 
nucleus into the cytoplasm (Lund et al. 2004; Yi et al. 2003). After export into the cytoplasm, the 
pre-miRNA is bound and further processed by a second RNase-III-like enzyme, Dicer, which 
cleaves the stem loop structure to generate a mature miRNA:miRNA* duplex ~21-23 bp in 
length (Bernstein et al. 2001; Ketting et al. 2001; Pasquinelli et al. 2000). One strand of the 
miRNA duplex is then loaded onto Argonaute (Ago) bound to GW182 (glycine and tryptophan 
repeats protein molecular weight of 182kD) to form an RNA-induced silencing complex (RISC) 
and usually, the strand that is less stably paired at the 5’ end is retained (Hammond et al. 2000; 
Schwarz et al. 2003). The mature miRNA then base-pairs imperfectly with cognate mRNA 
targets leading to translation repression, deadenylation and eventual target degradation (Krol, 
Loedige, and Filipowicz 2010).  
miRNAs have been detected in virtually every body fluid, including serum (Xi Chen et 
al. 2008), plasma (Freedman et al. 2016), breast milk (Nobuyoshi Kosaka et al. 2010), semen 
(Vojtech et al. 2014) and cerebrospinal fluid (CSF) (Lehmann et al. 2012). Specific sets of 
miRNAs have been found inside EVs, as well as in protein and lipid complexes. For example, 
miR-223 is enriched in HDL isolated from plasma of familial hypercholesterolemia patients 
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compared to healthy patients (Vickers et al. 2011). Additionally, miRNAs found in human 
plasma and serum can be bound to proteins, such as Ago2, that are not associated with EVs 
(Arroyo et al. 2011). Several studies have shown that in cancer, tumor-released EVs contain 
distinct miRNA profiles representative of the source tumor cell, with specific miRNAs enriched 
in EVs compared to their cell of origin. For example, let-7 family members are abundant in EVs 
secreted by metastatic gastric cancer cells, but not other cancer cells (Ohshima et al. 2010). In 
breast cancer cells, >99% of miR-451 is secreted by malignant cells, but preferentially retained in 
benign cancer cells (Pigati et al. 2010). Interestingly, miR-451 has been shown to act as tumor 
suppressor in certain cancers (Nan et al. 2010; Bitarte et al. 2011). Furthermore, we have 
previously shown miR-100 is preferentially secreted in EVs from mutant KRAS CRC cells (Cha 
et al. 2015) in a process that is dependent on KRAS status since miR-100 is not enriched in EVs 
released by wild-type KRAS CRC cells (Cha et al. 2015; H. Ji et al. 2014). These data suggest 
that miRNA packaging into EVs and other carriers occurs by a selective sorting process that can 
be differentially regulated in different cancers. 
 
 
Long non-coding RNAs (lncRNAs) 
lncRNAs are classically defined as RNA transcripts >200 nucleotides in length that lack 
significant open reading frames.  They are often 5’ capped and polyadenylated, consistent with 
transcription by RNA Polymerase II (Fatica and Bozzoni 2014). According to GENCODE 
(www.gencodegenes.org), the current Ensembl human genome annotation (CRch38, v23) 
identifies more than 27,800 transcripts from ~16,000 genes as lncRNAs. Expression of lncRNAs 
is typically cell- and tissue-specific and often implicated in the control of various homeostatic 
processes (Fatica and Bozzoni 2014). The deregulation of lncRNA expression has been 
associated with the development and progression of certain cancers, and has been linked to 
modulating oncogenic and tumor-suppressive pathways (Berrondo et al. 2016; Q. Ji et al. 2014). 
Although the majority of studies profiling various biofluids and conditioned media have 
focused on small RNAs (<200 nt) (Andrey Turchinovich et al. 2011), in certain contexts, 
lncRNAs are preferentially enriched in EVs. For instance, Prostate Cancer Antigen 3 (PCA3), or 
DD3, is a well-known lncRNA that is overexpressed in more than 95% of primary prostate 
cancers (PCa). Furthermore, PCA3 is readily identified in urine and has been implemented as the 
first urine-based molecular diagnostic test approved by the Food and Drug Administration (G. L. 
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Lee, Dobi, and Srivastava 2011). As its levels correlate with the tumor Gleason score, circulating 
PCA3 can also reflect the aggressiveness of prostate cancer (Merola et al. 2015). 
 
Circular RNAs (circRNAs) 
In Eukaryotes, circRNAs are covalently closed, single-stranded transcripts produced from 
back-splicing of genes, catalyzed by the spliceosomal machinery (Ashwal-Fluss et al. 2014). 
Discovered more than 30 years ago, they were traditionally thought to be by-products of aberrant 
splicing, with no known function (Capel et al. 1993; Cocquerelle et al. 1993). Recent advances in 
NGS of non-polyadenylated transcripts have found that circRNA expression is widespread (Jeck 
et al. 2013; Memczak et al. 2013; A. Ivanov et al. 2015; Dou et al. 2016). CircRNAs have cell- 
and tissue-specific expression patterns and can function as miRNA sponges (Hansen et al. 2013), 
competitors for complexes involved in normal splicing (Ashwal-Fluss et al. 2014), or as 
regulators of the local concentration of RNA-binding proteins (RBPs) (Memczak et al. 2013). 
We previously showed that circRNAs are globally down-regulated in mutant KRAS CRC cells, 
while specific circRNAs are enriched in their secreted exosomes (Dou et al. 2016). Expression 
levels of certain circRNAs, specifically circ-KLDHC10, were also shown to be significantly 
increased in serum EVs of CRC patients (Y. Li et al. 2015). In both cases, circRNAs in EVs 
were highly enriched compared to the levels of the corresponding linear RNAs, indicating that 
some circRNAs are more efficiently incorporated into EVs. 
 
tRNA-derived fragments (tRFs) 
One major class of RNA observed in circulation is tRNA fragments. tRNA undergoes 
several steps of processing and modification before becoming competent for translation (H. Li 
2007). tRNA fragments result from normal processing of tRNAs (constitutive) to produce tRNA-
derived fragments (tRFs)(Y. S. Lee et al. 2009), or in response to cell stress to produce tRNA-
derived half transcripts (tRH), also known as tiRNAs(Yamasaki et al. 2009). Constitutive tRFs 
are comprised of three general types: one produced by cleavage at the 3’-end of the pre-tRNA 
transcript by RNase Z (3’-U tRF), and two produced by cleavage of the mature tRNA at the 3’- 
(3’-CCA tRF) and 5’-ends (5’-tRF) by Dicer (Haussecker et al. 2010). Similar to miRNAs, these 
tRFs are approximately 19-22 nt in length. 3’-tRFs have been shown to preferentially associate 
with AGO3-4, and 3’-CCA tRFs can function to silence specific targets analogous to miRNAs 
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(Haussecker et al. 2010).  
In addition to constitutive tRFs, cell stress can induce tRNA cleavage into half-tRNA 
molecules by the ribonuclease angiogenin (ANG) (RNY1 in yeast (Thompson and Parker 2009)). 
ANG cleaves within the anticodon loops of mature tRNAs to produce 5’- and 3’-tRH that are 
~30 and ~40 nt, respectively (Yamasaki et al. 2009).  5’-tRH RNAs have been reported to bind 
eukaryotic initiation factor (eIF) 4G to relocate the preinitiation complex away from mRNA, 
subsequently causing translational repression and stress granule assembly (P. Ivanov et al. 2011). 
5’-tRH RNAs are abundant in blood plasma where they are hypothesized to associate with 
vesicle-free protein complexes such as HDL (Dhahbi, Spindler, Atamna, Yamakawa, et al. 
2013). In contrast to blood plasma, 5’-tRH RNAs are also abundantly found within seminal fluid 
EVs from healthy male donors (Vojtech et al. 2014). In addition to 5’-tRH, 5’-tRNA fragments 
represent the most abundant type of RNA found in EVs secreted by immune cells, with a unique 
size distribution of ~40-50 nt (E. N. M. N.-’t Hoen et al. 2012). It is unknown whether these 
fragments are produced through angiogenin-mediated cleavage or represent byproducts of 
normal tRNA processing. 
Although tRNA fragments make up a large percentage of exRNA, the functional 
consequences of their transfer to recipient cells are largely unknown. Considering that tRFs can 
be robustly induced upon cellular stress, it is likely that their expression patterns are altered in 
cancer. It was recently shown that a novel class of tRFs are induced in breast cancer cells, 
directly bind to Y-Box protein I (YBX1), and act to suppress the stability of multiple oncogenic 
transcripts by displacing YBX1 from the 3’-UTR (Goodarzi et al. 2015). Interestingly, YBX1 is 
required for the sorting of miR-223 to EVs in HEK293T cells (Shurtleff et al. 2016), and possibly 
other RNAs in different contexts. 
 
yRNA-derived fragments  
 yRNAs are a largely unexplored class of noncoding RNA species that have poorly 
characterized functions, but are best known as components of Ro and La ribonucleoproteins 
(RNPs), clinically significant autoantigens recognized by antibodies in patients with autoimmune 
disease (Sim and Wolin 2011; Lerner et al. 1981). Since their initial discovery, yRNAs have 
been shown to have additional functions, including formation of the DNA replication complex 
(Christo P. Christov et al. 2006) and chaperoning of misfolded RNAs (Kowalski and Krude 
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2015). In humans, the four yRNA genes are clustered together at a single chromosomal locus on 
chromosome 7q36 (Maraia et al. 1994). Individual yRNA genes are transcribed by RNA 
polymerase III from distinct promotors to produce transcripts of ~84-112 nt (Perreault et al. 
2005). The 5’ and 3’ RNA ends hybridize to fold into characteristic secondary stem-loop 
structures containing at least 3 stems (Teunissen et al. 2000). The nucleotide sequences within 
the stem regions are highly conserved, whereas the internal loop sequence is varied between 
individual yRNAs and across different organisms (Teunissen et al. 2000).  
In addition to the four annotated human yRNAs, yRNA fragments (yRFs) have been 
detected both intra- and extracellularly. Although some reports have shown that specific yRFs 
are a result of caspase-dependent cleavage and subsequent truncation during apoptosis (Rutjes et 
al. 1999), it is unclear whether all yRFs represent degradation products. Sequencing of small 
RNAs from tumor samples revealed yRFs ~25 nt in length, similar to miRNAs, are highly 
expressed in multiple cancer tissues (Meiri et al. 2010). Additionally, yRFs have been shown to 
associate with Ago2 in breast cancer cells (Thomson et al. 2015). These small yRFs reportedly 
do not possess miRNA-like activity (Meiri et al. 2010; Thomson et al. 2015) and are processed 
independent of the miRNA biogenesis pathway (Nicolas et al. 2012).  In addition to yRFs found 
within cancer cells and tumor samples, specific 5’-yRFs, approximately 27 nt and 30-33 nt, 
represent a large fraction of the total small RNAs present in human serum (Dhahbi, Spindler, 
Atamna, Boffelli, et al. 2013). Similarly, yRFs represent the most abundant class of RNA in EVs 
from endothelial cells, and are highly expressed in EVs from seminal fluid. Enrichment of 
specific yRFs are likely cell-type specific, since endothelial EVs are preferentially enriched for 
RNY5 fragments (Balkom et al. 2015), while RNY4 fragments appear to be the dominant yRF 
moieties in seminal fluid EVs (Vojtech et al. 2014). In both cases, however, the majority of 
sequences mapped to the 5’ ends of yRNA, suggesting selective sorting of yRFs into EVs may 
be regulated by common processing pathways that are presently unknown.  
 
Vault RNA fragments (vRFs) 
 In addition to yRNA and tRNA fragments, an abundant class of exRNA preferentially 
enriched in EVs compared to the cell is vault RNA (vRNA) fragments (vRFs). vRNAs are a 
family of cytoplasmic non-coding RNAs associated with vault RNP complexes containing 
multiple copies of major Vault protein (MVPs) (Kedersha and Rome 1986). Despite the known 
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roles of MVPs in intracellular and nucleocytoplasmic transport(J.-Y. Li et al. 1999; Chugani, 
Rome, and Kedersha 1993; Herrmann et al. 1999), the precise cellular functions of the vault 
RNAs are not well understood.  To date, there are three human vRNA genes arranged in a triple 
repeat on chromosome 5 that encode 98 nt (hvg1) or 88 nt (hvg2 and hvg3) single-exon pol III 
transcripts (Zon et al. 2001). A fourth vRNA-related sequence, hvg4, is located on the X-
chromosome, but is presumably a silent pseudogene(Zon et al. 2001).  
 Expression levels of vRNA vary substantially in human tissues, with high expression 
observed in lung, breast and adipose tissues (Persson et al. 2009; M. A. Izquierdo et al. 1996). 
Additionally, vRNAs have been found to be up-regulated in various cancers and can contribute 
to multi-drug resistance (Persson et al. 2009). In cancer cells, it was shown that the majority of 
vault complexes associate with hvg1, however, consistently more hvg3 was bound to vaults 
isolated from multi-drug resistant cells compared to their drug-sensitive counterparts (Zon et al. 
2001). Interestingly, hvg1 and hvg2 can specifically bind to mitoxantrone, a chemotherapeutic 
agent commonly used to treat breast cancer, myeloid leukemia and non-Hodgkin’s lymphoma 
(Gopinath et al. 2005). This suggests the ratio in which vRNA species are associated with vaults 
or chemotherapeutic drugs may be of functional significance. Furthermore, levels of vRNA are 
not always correlated with MVP abundance (M. A. Izquierdo et al. 1996), suggesting vRNA 
biogenesis occurs independently of its association with MVP. This raises the possibility that the 
accumulation of yRNAs may be mediated via transfer of extracellular vRNA derived from 
exogenous sources. 
It was recently demonstrated that vRNAs can be further processed into smaller ~23 nt 
fragments (vRFs) through a DICER-dependent and DROSHA-independent process (Persson et 
al. 2009). These vRFs can associate with Ago proteins to guide sequence-specific repression of 
target genes, similar to miRNAs (Persson et al. 2009). Interestingly, in immune cell exosomes, 
vRFs sequences predominantly correspond to the internal stem loop of the vRNA. In contrast, 
the bulk of cellular vRNAs are derived from 3’ and 5’ ends (E. N. M. N.-’t Hoen et al. 2012).  
Although it is unknown whether stem-loop derived fragments can also function as miRNAs or 
regulate target genes, differential accumulation in either cellular or exosomal samples suggests 
specific products of vRNA cleavage are preferentially incorporated into EVs . 
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1.2. Classes of EVs 
 
 
 EVs consist of a number of membrane encased cell-secreted vesicles. These include 
exosomes, microvesicles, apoptotic bodies, and oncosomes. As the nomenclature and exact 
purification strategies vary, (Gould and Raposo 2013), EVs provide a convenient term to refer to 
all secreted vesicles. Due to differences in their biogenesis, each class of EV likely have unique 
lipid composition, proteins and RNA cargo (Graça Raposo and Stoorvogel 2013), and distinct 
functional roles. This section will discuss some of these EV classes and what is known regarding 
their physical properties, composition and biogenesis. 
 
 
 
 
Figure 1. Origins and classes of exRNA carriers. (from Fritz et al. 2016).  During cell death, apoptotic 
bodies containing RNA are released into extracellular space (1). RNP complexes are likely also released 
during cell death (1), and from healthy cells (2), although no specific mechanisms have been described. 
Healthy cells also secrete exosomes (3), high-density lipoproteins (HDLs) (4), and microvesicles (5) 
associated with RNAs. In some cases, bacteria, viruses and fungi are able to hijack the mammalian export 
machinery to induce infected cells to release exogenous exRNAs through various carriers into circulation. 
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Exosomes 
Traditionally, exosomes are classified as the smallest EVs with a diameter of 50-150nm.  
These vesicle originate from the endosomal pathway and are secreted by fusion of late 
endosomes (also called multivesicular bodies; MVBs) with the plasma membrane (reviewed in 
(Colombo, Raposo, and Théry 2014; Maas, Breakefield, and Weaver 2016; Graça Raposo and 
Stoorvogel 2013)). On their way to becoming MVBs, the small membrane domains become 
enriched with various cargos including lipids, such as cholesterol, lysobisphosphatidid acid 
(LPBA), sphingomyelins and ceramide (reviewed in (Cocucci and Meldolesi 2015), which are 
also enriched in exosomes (Simpson, Kalra, and Mathivanan 2012). A critical component of 
MVB maturation and exosome formation is the accumulation and processing of ubiquitinated 
proteins sorted by the endosomal sorting complex required for transport (ESCRT) machinery 
(Colombo et al. 2013). In addition to ESCRT, exosomes can be generated through ESCRT-
independent mechanisms that appears to be cell-type specific. For example, in mouse 
oligodendroglial cells, production of exosomes requires the hydrolysis of sphingomyelin to 
ceramide by neutral sphingomyelinase (nSMase) (Trajkovic et al. 2008). Ceramide can undergo 
catabolism to produce sphingosine and sphingosine 1-phosphate (S1P) (Perry and Hannun 1998). 
S1P-mediated activation of Gi-coupled S1P receptors on MVBs is required for cargo sorting in 
exosomes of Hela cells (Kajimoto et al. 2013). According to EV databases ExoCarta and 
Vesiclepedia (Simpson, Kalra, and Mathivanan 2012; Kalra et al. 2012), the proteins most 
frequently enriched in exosomes are the tetraspanin family members CD9, CD63 and CD81, heat 
shock proteins Hsp70 and Hsp90, Flotillin-1, as well as enzymes involed in cellular metabolism, 
including Enolase1, Aldolase A, phosphoglycerate kinase 1 (PGK1) and lactate dehydrogenase 
A (LDHA)(Higginbotham et al. 2011a; Welton et al. 2010). 
 
Microvesicles 
Microvesicles (MVs), also known as shedding vesicles or ectosomes, are larger than 
exosomes, with a diameter of 0.15-1µm, and result from direct budding from the surface of the 
plasma membrane (Graça Raposo and Stoorvogel 2013). Consequently, the membrane 
composition of MVs reflects that of the parent cell more closely than does the membrane 
composition of exosomes (Andaloussi et al. 2013). MV shedding can be induced by asymmetric 
distribution of phospholipids in the plasma membrane, resulting in the exposure of 
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phosphatidylserine (PS) and phosphatidylethanolamine (PE) in the outer leaflet of the MV 
membrane (Larson et al. 2012; Lima et al. 2009). In cancer cells, shedding can also be induced 
by the ADP-ribosylation factor 6 (ARF6), a GTP binding protein that is enriched in MVs 
(Muralidharan-Chari et al. 2009, 6). Accumulation of protein and RNA cargoes in the MV lumen 
occurs by various mechanisms. Although the ESCRT machinery was initially thought to be 
important only for MVBs, ESCRTs have also been shown to regulate processes that are specific 
to the plasma membrane, such as membrane sorting, budding and fission during cytokinesis and 
virus budding (Bissig and Gruenberg 2014). For example, Tsg101, a component of ESCRT-I, 
can relocate to the plasma membrane to interact with Alix and Arrestin domain-containing 
protein 1 (ARDDC1) at the site of MV release (Nabhan et al. 2012). Additionally, ESCRT-III is 
a critical component for the abscission and release of MVs (Nabhan et al. 2012). In addition to 
ESCRT, internalization of proteins into MVs requires the binding of cytoplasmic proteins to the 
inner leaflet of the plasma membrane, which is often dependent on membrane anchors, such as 
myristoylation and palmitoylation, and higher-order polymerization that concentrates proteins to 
small membrane domains of MV budding (Shen et al. 2011; Yang and Gould 2013). 
 
Table 2. Characteristics of different extracellular vesicles 
 Exosomes Microvesicles Apoptotic Bodies Large oncosomes 
Diameter 50-150 nm 150-1000 nm >1000 nm 1-10 µm 
Origin Endosomes Plasma membrane  Plasma membrane 
of cells undergoing 
apoptosis 
Plasma membrane 
Markers Tetraspanins 
(CD63, 
CD81), 
Tsg101, 
flotillin 
Integrins, 
selectins, CD40, 
ARF6 
Phosphatidyl 
serine, annexin V, 
DNA 
KRT18 
Sedimentation  100,000 x g 10,000 x g ~2,000 x g 10,000-20,000 x g 
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Apoptotic Bodies (ABs) 
Cells undergoing apoptosis release large vesicles 0.5-2µm in diameter, known as 
apoptotic bodies (ABs), that results in nuclear fragmentation, increase in membrane 
permeability, and externalization of PS (Taylor, Cullen, and Martin 2008). As these vesicles are 
rich in PS, they aid in the clearance of corpses by phagocytes (Rubartelli, Poggi, and Zocchi 
1997). The generation of ABs occurs during the late stages of programmed cell death by caspase-
mediated cleavage and subsequent activation of ROCK1(Mills et al. 1998). Previously, ABs 
were thought to form stochastically (Taylor, Cullen, and Martin 2008), but it was recently shown 
in T-cells the biogenesis of these vesicles occurs in a tightly regulated multi-step process that 
involves the formation of ‘string-like’ membrane protrusion (also known as apoptopodia) after 
the onset of membrane blebbing (Poon et al. 2014). Although not well understood 
mechanistically, cellular contents such as cytokines, miRNA and DNA can be packaged into 
ABs to regulate immunity, tissue repair and tumorigenesis (Zernecke et al. 2009; Bergsmedh et 
al. 2001). Because apoptosis results in nuclear fragmentation, it has been reported that ABs 
contain nuclear material, such as DNA (Taille et al. 1999). Whether luminal transfer of ABs 
occurs in vivo and results in functional consequences requires further investigation. 
 
Oncosomes 
Oncosomes are the largest class of EVs (1-10um diameter) that bleb from the surface of 
metastatic cancer cell membranes (Di Vizio et al. 2012). Although the term oncosome has been 
used to describe a category of tumor-derived MVs, they are enriched for cargoes that are absent 
from typical MVs, such as Caveolin-1 and cytokeratin 18 (KRT18) (Di Vizio et al. 2012; 
Minciacchi et al. 2015), suggesting they represent a separate and distinct class of EVs. The 
abundance of oncosomes are reportedly correlated with tumor progression (Di Vizio et al. 2012), 
and can be induced by repression of cytoskeletal regulator Diaphanous-related formin-3 
(DIAPH3), by overexpression of certain oncogenes, or by activation of EGFR (Vizio et al. 2009; 
Hager et al. 2012; Kim et al. 2014). Less is known regarding the RNA cargo and functional 
importance of oncosomes in cell-to-cell communication compared to other classes of EVs. 
Nonetheless, it was shown that large oncosomes secreted by breast cancer cells are enriched for 
mRNAs encoding E2F transcriptional targets and histone proteins. These mRNAs are mostly 
expressed in S-phase of the cell cycle, suggesting their sorting into oncosomes may occur during 
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S-phase (Conley et al. 2016). In addition to mRNAs, certain miRNAs were selectively enriched 
in prostate cancer cell oncosomes to enhance migration of cancer-associated fibroblasts (CAFs) 
upon transfer (Morello et al. 2013). It is important to note, however, that due to limitations in 
isolation techniques, one cannot exclude the possible contribution of several EV populations to 
the reported protein and RNA profiles. Furthermore, because oncosomes, like MVs and ABs, are 
formed directly from the plasma membrane, it remains unclear whether these EVs are completely 
distinct, arise through different biogenic pathways and/or differ in their functional roles. 
 
1.3. Mechanisms of exRNA loading into EVs  
 
Among the different types of EVs, exosomes are perhaps the best studied and 
characterized. Given the lack of knowledge regarding RNA sorting into larger vesicles, this 
section will focus on RNA loading into exosomes. Although care must be taken when evaluating 
the different purification protocols and characterization between different reports, exosomes 
appear to carry a distinct repertoire of RNAs different from the parent cell of origin (Chiba 
2012).  This suggests a selective sorting process for exRNA in exosomes.  
Because exosomes arise through the endosomal pathway, it appears that RNA sorting 
into exosomes is regulated, at least in part, by subcellular localization of the RNA and its 
associated binding protein(s) (Figure 2). For example, inhibition of the Endosomal Sorting 
Complex Required for Transport (ESCRT) results in the accumulation of GW182, a component 
of the RISC machinery required for miRNA-mediated silencing, on the surface of late 
endosomes, (Gibbings et al. 2009). This results in compromised target mRNA repression and is 
consistent with the idea that RISC complexes localize to the surface of late endosomes or MVBs. 
Also consistent with the model that RISC activity affects miRNA sorting into EVs , depletion of 
GW182 or AGO2 reduces miRNA secretion in exosomes (Yao et al. 2012; Guduric-Fuchs et al. 
2012). In macrophages, cell-activation-dependent changes in mRNA levels can promote miRNA 
relocation from cytoplasmic P-Bodies (sites of miRNA repression) to the surface of MVBs (sites 
of RISC turnover and exosome biogenesis), thereby controlling miRNA secretion in exosomes 
(Squadrito et al. 2014). Furthermore, certain miRNAs can also undergo non-template directed 
nucleotide additions (NTAs) that alter miRNA activity, stability, and association with RISC (Wei 
et al. 2012; Burroughs et al. 2010; Thornton et al. 2014; Heo et al. 2012). As such, certain 
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miRNA isoforms that are 3’-uridylated appear to be enriched in exosomes compared to the 
parental cell (Koppers-Lalic et al. 2014). However, not all miRNAs undergo NTAs, suggesting 
additional targeting mechanisms exist.  
Similar to the fact that cis-acting elements in an RNA can regulate subcellular 
localization (Jambhekar and DeRisi 2007), miRNAs may also be sorted to EVs in a sequence-
dependent fashion. An exosome-sorting motif has been described for miRNAs secreted by T-
lymphocyte cells (Villarroya-Beltri et al. 2013a) consisting of a GGAG sequence within the 3’-
end of the miRNA (Villarroya-Beltri et al. 2013a). The hypothesis is that this sequence is 
recognized by a SUMOylated version of heteronuclear ribonucleoprotein (hnRNP) A2B1 which 
then targets the miRNA for export into exosomes. 
Another mechanism that may drive sorting specificity is through lipid-mediated RNA 
loading into EVs, specifically the sphingolipid ceramide (N. Kosaka et al. 2010). Reduction of 
ceramide synthesis by inhibition of neutral sphingomyelinase 2 (nSMase2) impairs exosomal 
maturation and release (Trajkovic et al. 2008), and is required for exosomal miRNA secretion in 
HEK293 cells (N. Kosaka et al. 2010). Interestingly, ceramide depletion through nSMase2 
inhibition increases transport of specific miRNAs on HDL (Vickers et al. 2011), suggesting that 
the secretion of miRNAs may occur through overlapping but distinct mechanisms. Similar to the 
bioactive role of ceramide, sphingosine-1-phosphate (S1P), a metabolite produced through 
acylation and phosphorylation of ceramide, is an essential component in exosomal maturation 
and release (Kajimoto et al. 2013).  It is unknown whether S1P affects RNA secretion. 
 Overall, these data suggest multiple biogenic routes exist for the secretion of RNAs in 
exosomes and EVs that may be cell-type and cell-state dependent. Whether these pathways are 
distinct and reflect the heterogeneity of EVs and their cargoes remains to be determined.  
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Figure 2. General model of miRNA biogenesis and export into exosomes. 1) miRNA genes are transcribed 
by RNA polymerase II as pri-miRNAs and 2) processed by Drosha in complex with DGCR8 to pre-miRNAs 
in the nucleus. 3) Pre-miRNAs are exported to the cytoplasm by Exportin-5, where they are further 4) 
processed into mature miRNA:miRNA* duplexes by Dicer. 5) The guide strand is bound by AGO and partner 
GW182, and preferentially retained in the RISC 6) where it base-pairs with target mRNAs to mediate target 
repression or cleavage localized to MVBs. MVBs arise from maturation of 7) early endosomes and form by 
inward budding into MVBs. MVBs can 8) be targeted to the lysosome, or 9) to the plasma membrane to 
release their intraluminal vescicles (exosomes; grey circles) into the extracellular space. 
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1.4. EV-mediated transfer of exRNA 
The current prevailing paradigm is that EVs are tiny “packages” of information that can 
reach various targets, representing a novel form of communication between cells. A key 
component is that EVs can provide exchange of genetic information, particularly in the form of 
RNA, and that this information can be transferred over long distances. As such, the functional 
output of exRNAs ultimately depends on its uptake by recipient cells. A variety of different 
mechanisms addressing internalization and release of luminal contents have been described in 
detail (Colombo, Raposo, and Théry 2014; Mulcahy, Pink, and Carter 2014). The primary 
pathways that have been demonstrated include endocytosis (Morelli et al. 2004; Nanbo et al. 
2013) and direct fusion to the plasma membrane (Montecalvo et al. 2012; Parolini et al. 2009). 
This section will review some of the modes of EV uptake as well as the functional consequences 
of RNA unloading in recipient cells (Figure 3). 
 
EV Uptake 
Considering the topology of EVs and the fact that they contain a variety of signaling 
proteins on their surface (Segura et al. 2005; Higginbotham et al. 2011a), most evidence suggests 
that EVs are taken up via endocytosis (Segura et al. 2005; Tian et al. 2010; E. N. M. N.-‘t Hoen 
et al. 2009; Higginbotham et al. 2011a).  This uptake can occur rapidly, with EVs being detected 
inside recipient cells as early as 15 minutes after  incubation (Feng et al. 2010). EV endocytosis 
can occur through various molecular internalization pathways, including clathrin- (Escrevente et 
al. 2011; Tian et al. 2014) and caveolin-mediated endocytosis (Nanbo et al. 2013),   
macropinocytosis (Nakase et al. 2015; Fitzner et al. 2011), and phagocytosis (Montecalvo et al. 
2012; Feng et al. 2010). In these cases, EV internalization requires subsequent back-fusion at the 
endosomal membrane for cytosolic RNA delivery, which may be facilitated by the acidic pH 
found in endosomes (Parolini et al. 2009). 
Another possible entry mechanism is by direct fusion of the EV membrane with the cell 
plasma membrane. Membrane fusion requires that two phospholipid bilayers merge to form an 
aqueous fusion pore (Jahn and Südhof 1999), connecting cytosolic compartments of the EV to 
the target cell. Although EV-uptake via fusogenic routes is energetically unfavorable (Jahn and 
Südhof 1999), and thus, less likely to occur, it was demonstrated that in dendritic cells, cell-to-
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cell transfer of miRNAs occurs through EV hemifusion with the plasma membrane of acceptor 
cells (Montecalvo et al. 2012). Additionally, exosomes produced by melanoma cells cultured in 
low pH display increased fusion and internalization by recipient cells (Parolini et al. 2009). 
Whether EV uptake depends on endocytic routes or direct fusion remains unclear. As no 
universal mechanism has been identified, it seems likely that specific recipient cells utilize 
distinct mechanisms for EV uptake that is influenced by the physiological state of the donor as 
well as the recipient cell (Mulcahy, Pink, and Carter 2014). 
 
Functional transfer of RNA 
Although the exact mechanism of uncoating remains to be determined, transfer of EV-
associated RNAs has been shown to have numerous effects in recipient cells. In cancer, these 
include mediating cell-to-cell transfer of oncogenic RNAs, modulation of the tumor 
microenvironment, and recruiting of pro-tumorigenic immune cells (Higginbotham et al. 2011a; 
Luga et al. 2012; Bobrie et al. 2012).  
One of the first functional studies investigating transfer of mRNAs tested delivery of 
mouse MC/9 EVs mRNAs into human mast cells (Valadi et al. 2007). Unfortunately, follow up 
studies on functional protein-coding mRNAs in circulation are lacking. Nonetheless, 
overexpression studies revealed the possibility of delivering functional mRNAs to target cells.  
Glioblastoma-derived microvesicles containing GLuc mRNA could be transferred to and 
expressed in recipient human brain microvascular endothelial cells (Skog et al. 2008).  
Additionally, an in vivo model showed that transplantation of lung carcinoma tumor cells 
expressing Cre recombinase into reporter mice led to Cre-mediated recombination events near 
the tumor site, suggesting Cre mRNA can be secreted in EVs and function on nearby cells 
(Ridder et al. 2015).  
Among the different types of exRNAs, most functional studies have focused on the 
consequences of miRNA transfer because reporter assays can easily be adapted (reviewed in (A. 
Turchinovich, Samatov, and Burwinkel 2013)). In theory, mRNA transfer should also be readily 
detectable but specific examples of mRNA transfer are limited (Batagov and Kurochkin 2013; 
Valadi et al. 2007). Besides canonical silencing of mRNAs via miRNA transfer, EV-derived 
miRNAs can also elicit non-canonical responses in target cells (Figure 3). Tumor-secreted miR-
21 and miR-29a can bind as ligands to Toll-like receptors (TLR) (murine TLR7 and human 
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TLR8) in immune cells to trigger inflammatory responses (Fabbri et al. 2012) that can facilitate 
tumor growth and metastasis. Interestingly, extracellular yRNA fragments associated with Ro60 
have also been shown to induce TLR7-dependent NF-KB activation in models of atherosclerosis 
(Hizir et al. 2017). Whether exRNA-mediated activation of TLRs has sequence-specific 
requirements or is restricted to immune cells remains to be determined. 
 
 
 
 
Insight into the role of EV-mediated transfer of RNAs other than miRNAs and mRNAs is 
only beginning to emerge. EV-derived RNAs from stromal cells can activate the pattern 
recognition receptor RIG-I to activate antiviral signaling in breast cancer cells (Boelens et al. 
2014). Typically, RIG-I activation occurs by viral RNA bearing 5’ triphosphate, but 
interestingly, stromal EVs predominantly contain transposable element RNAs, which can also 
have 5'-triphosphate ends (Dieci et al. 2013). Additionally, cancer cell secreted yRNA fragments, 
specifically yRNA5 (or RNY5), triggered rapid cell death when transferred to healthy primary 
cells, but not other cancer cells (Chakrabortty et al. 2015). Although the mechanisms are unclear, 
yRNAs are known to be significantly up-regulated in cancer tissues and can regulate cell 
Figure 3. Uptake and functions of extracellular small RNAs in target cells. (1) The scavenger receptor 
class B member 1 (SR-BI) has been shown to be involved in the uptake of high-density lipoprotein (HDL)-
associated miRNAs. (2) Small RNAs complexed in ribonucleoproteins (RNPs) have been found in 
circulation, but their uptake mechanisms remain largely unknown. RNAs encased in extracellular vesicles 
(EVs) can be taken up by (3) receptor-mediated endocytosis, or by (4) direct fusion with the plasma 
membrane of the target cell. After the RNA is released into the cytosol of acceptor cells, some exRNAs have 
been shown to cause (5) translational repression through the RNA-induced silencing complex (RISC), or 
immune activation by direct interaction with (6) Toll-like receptors (TLRs) found in late endsosomes, or 
trhough retinoic acid-inducible gene 1 (RIG-1). 
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proliferation (C. P. Christov, Trivier, and Krude 2008). Furthermore, transfer of CDR1as, a 
circRNA known to function as a miR-7 sponge (Hansen et al. 2013), from breast cancer cells to 
recipient liver cells abrogated miR-7-induced growth suppression (Y. Li et al. 2015). Thus, the 
transfer of these RNA moieties may reflect a novel strategy used by cancer cells to establish pro-
metastatic microenvironments. 
 
1.5. Quantitative analysis of exRNAs in EVs 
  
 
Despite growing evidence of EV-mediated RNA transfer as a mode of intercellular 
communication, current models lack quantitative and physiological significance of this 
paradigm. Quantitative analysis of miRNAs contained within exosomes demonstrated that on 
average, less than one miRNA molecule is found per exosome, representing 2.5% (median) of 
total secreted miRNAs from a variety of biological fluids (Chevillet et al. 2014). As several 
reports have shown that cells secrete a heterogenous population of EVs, one possibility is that 
miRNAs and other RNAs are only contained within specific subclasses of EVs. Some of these 
EVs might contain substantially high numbers of RNA molecules, while other EVs might 
contain no RNA cargo at all. Theoretically, an EV with a 150 nm diameter, containing a lipid 
bilayer 4 nm in width, has an internal radius of approximately 71 nm, to produce a maximum 
internal volume of (4/3πR3) ~1.5 x 10-12 nm3. Considering the calculated volume of a 100 nt 
RNA transcript, which is approximately 6 x10
-17
 nm
3
 (Voss and Gerstein 2005), one EV could 
thus tightly accommodate about 2.5 x 10
4
 small RNA molecules.  
Despite the reportedly low numbers of RNA cargo per EV, there can be up to 10
12
 EV 
particles per ml of body fluid (M. Li et al. 2014; Chevillet et al. 2014). Thus, as a population, 
RNAs encased within EVs can accumulate to high numbers in recipient cells. Furthermore, 
cellular uptake of exosomes between cells might be rapid and continuous, which would not 
necessarily be reflected in circulation or from conditioned media at steady state. Rapid uptake 
has been observed in macrophages, which can internalize an equivalent of their cell surface in 
pinocytic vesicles every 33 minutes (Steinman, Brodie, and Cohn 1976). In this case, low levels 
of circulating RNAs could accumulate to functionally sufficient quantities in target cells. 
Interestingly, mutant KRAS  pancreatic adenocarcinoma cells exhibit high levels of EV uptake 
via macropinocytosis compared to wild type KRAS cells (Nakase et al. 2015), suggesting a role 
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in RAS-mediated macropinocytosis of EVs in malignant progression. In addition to bulk uptake, 
the exchange of EVs and their associated RNAs might occur through direct cell-to-cell 
connections, such as tunneling nanotubes (TNTs) or gap junctions. In support of this, EVs 
derived from malignant cancer cells have been shown to increase the formation of TNTs (non-
adherent, actin-based cytoplasmic extensions), and that these TNTs function as conduits for 
intercellular transfer of EVs between connected cells (Thayanithy et al. 2014). Lastly, RNAs 
might function in non-canonical pathways where single copies are sufficient in eliciting a 
biological response. 
In the case of miRNAs or other small RNAs, another possibility is that these RNAs are in 
complex within vesicle-free RNPs, such as Ago2 (Arroyo et al. 2011), or as part of HDL 
complexes (Vickers et al. 2011; Tabet et al. 2014). These complexes have been shown to co-
sediment with EVs during common ultracentrifugation isolation procedures (Arroyo et al. 2011). 
Thus, it is possible that some of the RNAs described in EVs are perhaps not present in EVs at all, 
but in other co-isolating carriers. Whether these RNP-associated miRNAs are secreted by active 
processes in donor cells, and how these miRNAs reassemble into functional RISC in recipient 
cells remains to be defined. 
Quantitative evaluation regarding the stoichiometric ratio of RNA transcripts per EV and 
in circulation outside of EVs will be essential to understanding the requirements and limits of 
exRNA-mediated communication. As more sequencing profiles and data sets are being 
generated, a comprehensive model to determine the contents of each EV and how likely those 
contents contribute to physiological processes will be of critical importance. Despite most 
studies indicating a general enrichment of small RNA species in EVs, among the RNA 
candidates most likely to confer changes in recipient cells are those that can be amplified, such 
as mRNAs, which can be translated repeatedly to produce many proteins. Thus, just a few 
mRNA molecules would be sufficient to illicit significant changes in acceptor cells. Alternately, 
the RNA product, or the RNA itself, could have regulatory functions. 
  
 
1.6 Conclusions 
   
 
Accumulating evidence demonstrates the importance of exRNA in normal development 
as well as in pathological processes. However, a caveat of the field is that most studies on EV-
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mediated RNA transfer have been based primarily on in vitro experiments or ex vivo 
manipulations, leaving their physiological relevance unclear. It is well documented that different 
cell types differ in the composition of RNAs and EVs that they secrete, as well as their 
propensity for EV-mediated uptake. There is promising potential for EV-derived exRNAs as 
disease biomarkers and their applications in cancer immunotherapy. However, the mechanisms 
involved in EV secretion and cargo loading, as well as their interaction with target cells is only 
beginning to emerge. It is important to recognize that apart from mRNAs and miRNAs, other 
RNA classes may act as signaling molecules. It will important to determine the mechanisms that 
determine selective RNA export, how EVs are targeted to specific cells, and how exRNAs are 
released in recipient cells to alter gene expression patterns.   
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Chapter 2 
 
 
KRAS-dependent sorting of miRNA to exosomes
1 
 
 
2.1 Abstract 
 
Mutant KRAS colorectal cancer (CRC) cells release protein-laden exosomes that can alter the 
tumor microenvironment.  To test whether exosomal RNA might also contribute to changes in 
gene expression in recipient cells, and to test whether mutant KRAS might regulate the 
composition of secreted miRNAs, we compared small RNAs of cells and matched exosomes 
from isogenic CRC cell lines differing only in KRAS status.  We show that exosomal profiles are 
distinct from cellular profiles, and mutant KRAS exosomes cluster separately from wild type 
KRAS exosomes.  miR-10b was selectively increased in wild type KRAS exosomes while miR-
100 was increased in mutant KRAS exosomes.  Neutral sphingomyelinase inhibition caused 
accumulation of miR-100 only in mutant KRAS cells, suggesting KRAS-dependent miRNA 
export.  In Transwell co-culture experiments, mutant KRAS donor cells conferred miR-100-
mediated target repression in wild type KRAS recipient cells.  These findings suggest 
extracellular miRNAs can function in target cells and uncover a potential new mode of action for 
mutant KRAS in CRC. 
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2.2 Introduction 
An emerging paradigm in the study of cell signaling is the potential role for post-
transcriptional gene regulation by extracellular RNAs.  microRNAs (miRNAs) are perhaps the 
best characterized class of small noncoding RNAs that have been detected in extracellular fluids 
(Valadi et al. 2007).  Mature miRNAs are 21-23 nucleotides in length and bind to target mRNAs 
to inhibit their expression (Krol, Loedige, and Filipowicz 2010).  Because miRNAs imperfectly 
pair with their mRNA targets, they can potentially regulate hundreds of transcripts within a 
genome(Bartel 2004).  However, individual miRNAs exhibit exquisite tissue-specific patterns of 
expression(Wienholds 2005), control cell fate decisions(Alvarez-Garcia and Miska 2005), and 
are often aberrantly expressed in human cancers(Calin and Croce 2006), affording possible 
disease-specific signatures with diagnostic, prognostic and therapeutic potential(J. Lu et al. 2005; 
Volinia et al. 2006).  
In addition to their intracellular roles, recent experiments have identified miRNAs outside 
the cell in extracellular vesicles (EVs) including exosomes or larger vesicles(Valadi et al. 2007; 
Graça Raposo and Stoorvogel 2013), in high density lipoprotein (HDL) particles(Vickers et al. 
2011), or in smaller complexes with Argonaute 2 protein (AGO2)(Arroyo et al. 2011).  
Exosomes are small 40-130nm vesicles of endosomal origin that are secreted by all cells and can 
fuse and be internalized by recipient cells(Valadi et al. 2007; N. Kosaka et al. 2010).  It has been 
suggested that protein cargo transfer by exosomes between cells is associated with tumor 
aggressiveness and metastasis(Skog et al. 2008; Higginbotham et al. 2011a; Luga et al. 2012; 
Hoshino et al. 2013).  With the discovery that miRNAs and other RNAs can also be packaged 
into EVs, or exported by other extracellular mechanisms, it remains unclear the extent to which 
RNA cargo is sorted for export and how it is dysregulated in disease conditions, such as cancer.  
Despite accumulating evidence that exosomes are biologically active, little is known 
regarding how oncogenic signaling affects the repertoire of miRNAs or proteins that are selected 
for secretion.  Given the potential of cancer-derived secreted RNAs to modulate the tumor 
microenvironment, elucidation of the potential mechanisms for selective sorting of cargo into 
exosomes is critical to understanding extracellular signaling by RNA.  KRAS mutations occur in 
approximately 34-45% of colon cancers(Wong and Cunningham 2008).  We have previously 
shown that exosomes from mutant KRAS CRC cells can be transferred to wild type cells to 
induce cell growth and migration(Higginbotham et al. 2011a; Demory Beckler et al. 2012).  
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Compared to exosomes derived from isogenically matched wild type cells, exosomes derived 
from mutant KRAS cells contain dramatically different protein cargo(Demory Beckler et al. 
2012).  Here, we show that KRAS status also prominently affects the miRNA profile in cells and 
their corresponding exosomes.  Exosomal miRNA profiles are distinct from cellular miRNA 
patterns and exosomal miRNA profiles are better predictors of KRAS status than cellular miRNA 
profiles.  Furthermore, we show that cellular trafficking of miRNAs is sensitive to neutral 
sphingomyelinase inhibition in mutant, but not wild type, KRAS cells and that transfer of 
miRNAs between cells can functionally alter gene expression in recipient cells.  
 
2.3. Results 
Small noncoding RNAs are differentially distributed in exosomes 
Because small RNAs are thought to be sorted at endosomal membranes and since KRAS 
signaling can also occur on late endosomes(A. Lu et al. 2009), we hypothesized that oncogenic 
KRAS signaling could alter RNA export into exosomes.  We prepared small RNA libraries from 
both exosomes and whole cells using isogenically matched CRC cell lines that differ only in 
KRAS status (Table 2)(Senji Shirasawa et al. 1993).  Exosomes were purified using differential 
centrifugation and consisted of vesicles ranging in size from 40-130 nm(Higginbotham et al. 
2011a; Demory Beckler et al. 2012).  These preparations exclude larger microvesicles but 
contain smaller lipoproteins and probably other small RNA-protein complexes (unpublished 
observation).  Comprehensive sequencing analyses of both cellular and exosomal small RNAs 
from all three cell lines revealed that more than 85% of the reads from the cellular RNA libraries 
mapped to the genome, compared to only 50-71% from the exosomal libraries (Figure2A).  The 
non-mappable reads consisted largely of sequences that contain mismatches to genomic 
sequences.  
The global small RNA profiles identified reads from various classes of RNA, including 
miRNAs, with differential enrichment of specific RNAs in both the cellular and exosomal 
fractions.  Compared to cellular RNA samples, which displayed an enrichment of miRNA 
sequences (~70%), miRNA reads in exosomal samples comprised a smaller percentage of the 
total small reads (5-18%) compared to other ncRNA classes (e.g. tRNAs, rRNAs, snRNAs) 
(Figure 4B,C).  Most of these reads appear to be fragments of larger RNAs, both cytoplasmic 
and nuclear.  It is not clear how these RNAs are associated with and/or deposited into exosomes.  
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Table 3.  Colorectal cancer cell lines. 
Cell line KRAS allele Growth in soft agar Tumors in nude 
mice 
DLD-1 WT/G13D Yes Yes 
DKs-8 WT No No 
DKO-1 G13D Yes Yes 
Small RNA sequencing libraries were prepared from three isogenic colorectal cancer cell lines with the indicated 
alleles of KRAS. Table is based on work done in (Senji Shirasawa et al. 1993). 
 
 
 
 
 
   
  
Figure 4. Small RNA sequencing analysis of cellular and exosomal RNAs from CRC cell lines. 
Shown are (A) total read numbers (y-axis) and the total percentage of mappable reads (red), percentage of 
unique mappable reads (green), reads that map to multiple genomic locations (dark blue), and those that 
could not be mapped (cyan). (B) The majority of mappable small RNA reads were derived from 
noncoding RNAs in cells and exosomes. In cells, the majority of small RNA reads mapped to microRNAs 
(miRNAs) (miRbase 19), whereas in exosomes, the majority of small RNA reads mapped to repetitive 
elements. (C) The origin of repetitive reads from exosomal small RNA sequencing is shown. Repeat 
reads were annotated based on RepeatMasker and Rfam classified into tRNAs, rRNAs, snRNAs, and 
others. (D) The length distribution of reads mapping to miRNA hairpins was determined for small RNA 
reads from the three CRC cell lines and their purified exosomes. Colors represent the nucleotides 
identified for the 5′ base, T (cyan), A (red), G (green), and C (blue)  
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The size distribution of cellular small RNA matched that expected from miRNA-derived 
reads (21-23 nucleotides).  However, the small RNA read distribution from exosomes was much 
broader with many reads smaller than 22 nucleotides in length(A.1).  Given that these reads map 
to RNAs other than known miRNAs, these data suggest that a large proportion of small 
exosomal RNA reads are derived from processing of other RNAs, in addition to post-
transcriptionally modified miRNA reads that are apparently subject to editing, trimming, and/or 
tailing(Koppers-Lalic et al. 2014).  Consistent with this, when read identity was restricted to 
miRNAs by mapping back to known miRNA hairpin sequences, the length distribution of 
mappable reads was nearly identical between cells and exosomes (Figure 4D).  
 
miRNAs are differentially enriched in exosomes dependent on KRAS status 
Focusing on mappable reads, we sought to ascertain whether miRNAs might be 
differentially represented when comparing cells to their secreted exosomes.  For this, we 
quantified the relative abundance of individual miRNAs and made pairwise comparisons 
between normalized miRNA reads.  Spearman correlation analyses demonstrated high 
correlation between replicates of individual cell lines (r=0.95-0.96) and between cellular datasets 
differing only in KRAS status (r=0.92-0.96) (A.2,A.3).  In contrast, the miRNA profiles from 
exosomes compared to their parent cells were less correlated (DKO-1 r=0.67-0.81, DKs-8 
r=0.64-0.71, DLD-1 r=0.64-0.69) (A.2, A.3).   
We next utilized Principal Component (PC) analysis to determine whether the overall 
miRNA profiles could distinguish between cells and exosomes and/or between wild type and 
mutant KRAS status.  The miRNA profiles from the three cell lines all clustered close to one 
another indicating that overall miRNA expression profiles are fairly similar among the different 
cell types (Figure 5).  In marked contrast, Principal Component analysis revealed that exosomal 
miRNA profiles clearly segregate according to KRAS status (Figure 5).  Relatively minor 
differences between cellular miRNA expression profiles become much more prominent when 
comparing exosomal miRNA patterns (A.3).  This indicates that the presence of a mutant KRAS 
allele alters sorting of specific miRNAs to exosomes, a finding that has potentially important 
implications for biomarker development.  
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To gain more insight into the relative abundance of miRNAs in cells versus matched 
exosomes, we examined the most abundant miRNA species in the various sequencing libraries 
(determined by mean reads of individual miRNAs).  For many miRNAs, exosomal abundance 
correlated with cellular abundance. However, calculation of fold-changes among the three 
isogenic KRAS cell lines, and exosomes released from these cells, showed that distinct subsets of 
miRNAs are enriched in either exosomes or cells (Tables 4,5).  For all three cell lines, 25 
miRNAs were consistently up-regulated in cells and 29 miRNAs were consistently up-regulated 
in exosomes (Figure 6A,B).  Additionally, the diversity of miRNAs was substantially greater in 
mutant KRAS DKO-1 exosomes (94 unique miRNAs) compared to parental DLD-1 or wild type 
KRAS DKs-8 exosomes (Figure 6B).  A select subset of cell and exosomally targeted miRNAs 
were validated separately by qRT/PCR (Figure 6C).  Collectively, these data indicate that the 
miRNA profiles observed in exosomes are distinct from their parental cells with specific 
Figure 5. Small RNA composition segregates with KRAS status. 
Principal component analysis was performed comparing small RNA sequencing data sets from CRC cells and 
exosomes. The small RNA composition from cells differed significantly from exosomes. Nevertheless, 
clustering showed that mutant KRAS status could be inferred from small RNA composition.  
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miRNAs preferentially overrepresented or underrepresented in exosomes.  We observed a mutant 
KRAS-specific pattern of secreted miRNAs, consistent with the hypothesis that dysregulation of 
miRNA metabolism is associated with tumorigenesis, a previously unrecognized feature of 
mutant KRAS.  
 
KRAS-dependent sorting of miRNAs 
miR-100 
Down regulation of miR-100-5p was observed in mutant KRAS DKO-1 and parental 
DLD-1 cells compared to wild type KRAS DKs-8 cells (Table 4).  This is consistent with reports 
that have shown decreased miR-100 expression in metastatic cancers(Petrelli et al. 2012; 
Gebeshuber and Martinez 2013). miR-100 has also been shown to negatively regulate migration, 
invasion, and the epithelial-mesenchymal transition(D. Chen et al. 2014; M. Wang et al. 2014; 
Zhou et al. 2014). Interestingly, miR-100 was enriched in exosomes derived from mutant KRAS 
cells (>8-fold and >3-fold enriched in DKO-1 and DLD-1 exosomes, respectively), suggesting 
that decrease of miR-100 in cells is due to secretion in exosomes.  This is in line with findings 
that circulating levels of miR-100 are up-regulated in the plasma of mutant KRAS-expressing 
mouse pancreatic cancer models and in pancreatic cancer patients(LaConti et al. 2011).  More 
broadly, the observation that miR-100-5p specifically accumulates in exosomes suggests there 
may be sequence-specific requirements for the sorting of certain miRNAs into exosomes.  
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Figure 6.  KRAS-dependent regulation of miRNAs in exosomes and cells. 
Differentially distributed miRNAs in (A) cells and (B) exosomes from the three CRC cell lines differing 
in KRAS status. (C) qRT-PCR validation of selected miRs from DKs-8 and DKO-1 cellular and exosomal 
RNA samples normalized to U6 snRNA. Fold changes were calculated using the ΔΔC(t) method comparing 
exosomes to cells. Negative fold changes indicate greater enrichment in cells, and positive fold changes 
indicate greater enrichment in exosomes.  
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miR-10b  
Our RNA sequencing data identified miR-10b as preferentially secreted in exosomes 
isolated from cells harboring a wild type KRAS allele (>3 fold-change and >2 fold-change 
enrichment in DKs-8 and DLD-1 exosomes, respectively), but retained in mutant KRAS DKO-1 
cells (~3 fold-change cell enrichment).  miR-10b is referred to as an oncomiR because it is 
frequently up-regulated during progression of various cancers, including CRC(Ma et al. 2010).  
 
miR-320  
 miR-320 is aberrantly expressed in several types of cancer, including colon cancer.  It is 
expressed in the proliferative compartment of normal colonic crypts(Schepeler et al. 2008; Hsieh 
et al. 2013).  miR-320 members (miR-320b, -c, d, and -e) were abundant in both mutant KRAS 
(DKO-1) and wild type KRAS (DKs-8) exosomes, but underrepresented in the matched cells, 
indicating that some miRNAs are transcribed and predominantly exported into exosomes, 
independent of KRAS status (Table 4).  Of these family members, miR-320a and -320b were the 
most abundant species represented in exosomes by our RNA sequencing analyses (miR-320a in 
DKO-1 exosomes, and miR-320b in DKs-8 and DKO-1 exosomes).  Interestingly, however, we 
observed the largest enrichment for miR-320d (fold-changes >241 in DKs-8 and >229 in DKO-1) 
in exosomes relative to cells, despite being ~4-fold less abundant than miR-320b levels.  Because 
the 3’-terminus may be important in regulating miRNA stability and turnover, coupled to the fact 
that the sequences of miR-320a-d members differ only at their 3’-termini, enrichment of certain 
miRNAs in exosomes could be due to higher turnover/decay rates in cells.  
 
Exosomal secretion and strand selection 
 Because we observed differential export of specific miRNAs, we investigated whether 
there might be miRNA sequence-specific sorting signals.  Previous reports have shown 
differential accumulation of 5p or 3p strands in exosomes compared to parental cells(H. Ji et al. 
2014).  Thus, we analyzed our data sets to test whether exosomes might be preferentially 
enriched for one strand over the other.  We were able to identify individual miRNAs where the 
two strands differentially sorted between cells and exosomes.  For example, the -5p strands of 
miR-423 were overrepresented in DKO-1 exosomes but in exosomes from DKs-8 cells, both 
strands were overrepresented compared to cells (data not shown).  This indicates that KRAS 
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status may differentially affect selection of passenger or guide strands for sorting into exosomes 
for select individual miRNAs.   
Individual miRNAs often exist as populations of variants (isomiRs) that differ in length 
and/or nucleotide composition generated by template- or non-template-directed 
variation(Burroughs et al. 2010; Newman, Mani, and Hammond 2011; Neilsen, Goodall, and 
Bracken 2012).  When we analyzed our sequencing data sets, we did not detect differential 
accumulation of isomers with variable 5’ termini (data not shown).  For cellular miRNAs, most 
reads were full length with a slight enrichment in 3’ non-template addition (NTA) of A-tailed 
miRNAs, regardless of KRAS status (Figure 7; A.6).  For exosomes, we observed a slight 
enrichment for C residues added to the 3’ ends of miRNAs from wild type KRAS cells. We did 
not observe this in mutant KRAS exosomes, where instead, we noticed an increase in 3’ trimming 
of miRNAs (Figure 7, A.7).  Overall, it remains to be determined whether such modifications 
constitute a global exosomal sorting signal in these cells.   
 
 
 
Figure 7. Comparison of miRNA 3′ trimming and tailing between cells and exosomes. 
Overall changes in either 3′ nucleotide additions (tailing) or 3′ resection (trimming) compared to full length miRNA 
sequences (intact). Overall, the patterns between cells and between exosomes are very similar. A comparison of cells 
to exosomes shows that exosomes display a slight increase in trimmed miRNAs. 
  
34 
 
 
Consistent with published data, we have shown that miRNA expression patterns vary 
between parental cells and their cognate exosomes (Tables 4,5; Figure 6). Differential export 
suggests that specific signals must exist to sort distinct miRNAs(Batagov, Kuznetsov, and 
Kurochkin 2011; Villarroya-Beltri et al. 2013a).  We therefore conducted MEME analysis to 
attempt to identify sequence motifs that might serve as targeting signals.  When we examined all 
miRNA reads detected in exosomes, we did not find any global enrichment for specific 
sequences or motifs, including those reported to be bound by hnRNP A2B1 (GGAG or 
U/CC)(Bolukbasi et al. 2012; Villarroya-Beltri et al. 2013a) (A.8).  However, when we analyzed 
miR-320 because it is preferentially exported to exosomes independent of KRAS status, we were 
able to identify the GGAG sequence contained within the 3’ end of the mature sequence.  
Additionally, upon restricting our analysis to reads from the most differentially expressed 
miRNAs when comparing exosomes to cells, we found a slight enrichment for C residues, 
possibly alternating C residues in exosomal miRNAs(A.8).  
 
Sphingomyelinase-dependent sorting of miRNAs to exosomes 
Although little is understood regarding the molecular mechanisms for packaging 
exosomal miRNAs, recent evidence suggests that the secretion of miRNAs in exosomes is 
dependent on ceramide via its production by neutral sphingomyelinase 2 (nSMase2)(Nobuyoshi 
Kosaka et al. 2010; Mittelbrunn et al. 2011).  Inhibition of de novo ceramide synthesis by 
treatment with a neutral sphingomyelinase inhibitor impaired exosomal miRNA release, 
apparently due to decreased formation of miRNA-containing exosomes(Nobuyoshi Kosaka et al. 
2010; Mittelbrunn et al. 2011).  To test the role of neutral sphingomyelinase in miRNA secretion 
in our system, we treated CRC cells with the nSMase inhibitor, GW4869.  We determined the 
effect of this inhibitor on miR-10b since it is preferentially found in wild type KRAS DKs-8 
exosomes, miR-100 since it is preferentially found in mutant KRAS DKO-1 and DLD-1 
exosomes, and miR-320 which sorts into exosomes regardless of KRAS status.  For miR-10b, we 
did not observe significant changes in its cellular levels after treatment with GW4869 in either 
wild type KRAS DKs-8 or mutant KRAS DKO-1 cells (Figure 8C).  In contrast, inhibition of 
neutral sphingomyelinase caused a ~3-fold increase in intracellular levels of miR-100 in mutant 
KRAS DKO-1 cells but remained unchanged in wild type DKs-8 KRAS cells (Figure 8).  
Similarly, miR-320 levels were found to increase (~2.5 fold) only in GW4869-treated mutant 
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KRAS DKO-1 cells (Figure 8C).  These data are most consistent with the hypothesis that 
impaired ceramide synthesis alters cellular accumulation of miRNAs dependent on mutant KRAS 
and suggest that multiple biogenic routes exist for miRNA secretion. 
 
 
 
Figure 8. Ceramide-dependent miRNA export into exosomes. 
DKO-1 or DKs-8 cells were treated with an inhibitor of neutral sphingomyelinase 2 (nSMase 2), GW4869. After 
treatment, in situ hybridization experiments were performed with probes against miR-100 (A, B). (C) qRT-PCR 
formiR-10b, miR-100, and miR-320a was performed on cells treated with GW4869 or DMSO, and fold change in 
expression was determined in treated vs untreated cells. In wild-type KRAS cells (DKs-8), inhibition of nSMase 2 
had little or no effect on the cellular levels of these miRNAs. In contrast, mutant KRAS cells (DKO-1) showed an 
increase in cellular miRNA levels after inhibition of nSMAse 2. Data were derived from three biological replicates 
and performed in technical triplicates for qRT-PCR. Significance was determined by two-tailed, paired t-tests where 
* are p values ≤ 0.05 and ** ≤0.01.  
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Extracellular transfer of miR-100  
Several reports have found that extracellular miRNAs can be taken up by recipient cells 
to mediate heterotypic cell-cell interactions and facilitate target repression in neighboring 
cells(Mittelbrunn et al. 2011; Boelens et al. 2014; Squadrito et al. 2014).  To determine whether 
secreted miRNAs function in recipient cells, we designed luciferase (Luc) constructs containing 
either 3 perfect miR-100 recognition elements (MREs) in the 3’ UTR (Luc-100-PT) or scrambled 
3’ UTR sequences that do not match any known miRNAs (Luc-CTL).  These constructs were 
expressed in wild type KRAS DKs-8 cells (recipient cells) in the presence or absence of donor 
cells.  Baseline repression of Luc in the absence of donor cells was first analyzed to determine 
the levels of repression from endogenous miR-100 in DKs-8 cells.  Compared to the scrambled 
control (Luc-CTL), strong Luc repression in the absence of donor cells was observed with 
perfect miR-100 recognition elements (miR-100-PT) (Figure 9A).  This supports our finding that 
miR-100 is expressed and retained in DKs-8 cells.   
To determine whether secretion of miR-100 by mutant KRAS DKO-1 donor cells could 
further augment miR-100 function in recipient wild type cells, Transwell co-culture experiments 
were performed with DKs-8 recipient cells expressing the luciferase reporters in the presence of 
DKO-1 donor cells (Figure 9).  Significantly increased repression of Luc was observed when the 
reporter construct containing three perfect miR-100 sites was used (miR-100-PT)(Figure 9A).  
Because exosomes released from DKO-1 cells contain abundant levels of miR-100, increased 
luciferase repression is consistent with transfer of additional copies of miR-100.  Two control 
experiments were performed to test the hypothesis that additional copies of miR-100 are 
transferred between donor and recipient cells.  First, we treated donor cells with antagomirs that 
block production of miR-100.  Luc repression was almost completely reversed upon pretreatment 
of DKO-1 donor cells with a miR-100 hairpin antagomir inhibitor (AI-100) (Figure 9D).  Second, 
we performed qRT/PCR to calculate the increase in miR-100 levels in recipient cells.  Cells 
grown in the presence or absence of donor cells showed an approximate 34% increase in the 
levels of miR-100 (Figure 9E and A.9).  
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Figure 9. Transfer of extracellular miRNAs by mutant DKO-1 cells promotes target repression in wild-type 
DKs-8 cells. Transwell co-culture of DKs-8 recipient cells with or without DKs-8 or DKO-1 donor cells. Luciferase 
(Luc) expression was measured in DKs-8 recipient cells transiently expressing (A) Luc fused to three perfectly 
complementary syntheticmiR-100 target sites (miR-100-PT) or (B) Luc fused to the 3′UTR of mTOR, which harbors 
3 endogenous target sites for miR-100. (C) Luc expression increased upon mutation of two (MS2) sites with full 
expression upon mutation of all three sites (MS3). Luc-CTL contains three random scrambled target sites that do not 
match any known miRNA sequence. (D) Luc expression was restored in recipient cells expressing miR-100-PT upon 
pretreatment of donor DKO-1 cells with 100 nM miR-100 antagomirs (AI-100) compared to pre-treatment of donor 
DKO-1 cells with 100 nm control antagomirs (AI-CTL) targeting cel-miR-67. (E) Taqman qRT-PCR for miR-100. 
Compared to DKs-8 recipient cells grown without donor cells, mir-100 levels increased by approximately 34% in 
the presence of mutant DKO-1 donor cells pre-treated with AI-CTL compared to an 8% increase in AI-100 pre-
treated donor cells. Y axis is % increase in miR-100= (CPAI-CTL or CPAI-100 − CPno donor/CPno donor)
*
100, where CP = 
absolute copy number. All Luc values were normalized to co-transfected vectors expressing β-galactosidase; n = 3 
independent experiments in A–Cand n = 4 in D, E. All Luc assays were performed in technical triplicate. 
Significance was determined by two-tailed, paired t-tests where * are p values ≤ 0.05 and ** ≤0.01.  
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To further probe the repressive activity of miR-100, we performed co-culture experiments 
in which the recipient Dks-8 cells express Luc fused to the 3’UTR of mTOR, an endogenous 
miR-100 targe(Nagaraja et al. 2010; Grundmann et al. 2011; Ge et al. 2014).  As observed with 
miR-100-PT repression, Luc-mTOR was significantly repressed in the presence of mutant KRAS 
DKO-1, but not in the presence of wild type KRAS DKs-8 donor cells (Figure 9B).  This suggests 
that miR-100 repressive activity is specific to the presence of mutant KRAS DKO-1 donor cells.  
To confirm these results, we mutated the miR-100 recognition elements within the mTOR 3’UTR 
and assayed for miR-100 activity (A.10).  Mutation of individual sites did not show significantly 
different Luc repression (data not shown).  However, upon mutation of two MREs (MS2), we 
observed a partial rescue of Luc expression (Figure 9C).  This was further augmented upon 
mutation of all three sites (MS3), with a complete rescue of miR-100-mediated repressive 
activity (Figure 9C).   
As a final test of miRNA transfer in the Transwell co-culture experiments, we created 
vectors expressing Luc fused to a 3’ UTR containing perfect sites for miR-222 because miR-222 
is not detectable in DKs-8 recipient cells, unlike miR-100.  In this case, silencing of Luc should 
be due to transfer of miR-222 and not due to unforeseen changes in endogenous miRNA activity.  
We observed a greater than 2-fold repression of the miR-222 Luc reporter in recipient cells (A.11 
).  These results support the hypothesis that miRNAs secreted by mutant KRAS cells can be 
transferred to recipient cells.   
 
 
2.4 Discussion 
 
 
In this study, we comprehensively examined the composition of small ncRNAs from 
exosomes and cells of isogenic CRC cell lines that differ only in KRAS status.  By employing 
small RNA transcriptome analyses, we found that oncogenic KRAS selectively alters the miRNA 
profile in exosomes and that ceramide depletion selectively promotes miRNA accumulation in 
mutant KRAS CRC cells.  Distinct miRNA profiles between cells and their exosomes may be 
functionally coupled to mitogenic signaling.  
KRAS status-specific patterns of secreted miRNAs supports the idea of using exosomes as 
potential biomarkers in CRC.  Our finding that miR-10b is preferentially enriched in wild type 
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KRAS-derived exosomes while miR-100 is enriched in mutant KRAS-derived exosomes raises 
interesting questions regarding how they are selected for secretion.  miR-10b and miR-100 are 
both part of the miR-10/100 family and differ by only one base in the seed region, allowing 
regulation of distinct sets of target mRNAs (Tehler, Høyland-Kroghsbo, and Lund 2011).  
Whether the accumulation or export of these miRNAs is a result or a consequence of oncogenic 
signaling remains unknown.  Preventing the export or retention of certain miRNAs, such as miR-
100 and miR-10b, may serve a therapeutic role in reversing the tumorigenic effects seen with 
aberrant miRNA expression. 
 KRAS-dependent differential miRNA expression more prominently affected miRNA 
expression patterns observed in exosomes than in the parent cells.  This could reflect a 
mechanism by cells to selectively export miRNAs so as to maintain specific growth or gene 
expression states.  This is consistent with a recent report that found that the cellular levels of 
miR-218-5p could be maintained, despite changes in the abundance of its target, likely through a 
“miRNA relocation effect” where unbound miRNAs that are in excess have the potential to be 
sorted to exosomes(Squadrito et al. 2014).  Another mechanism may be through sequence-
specific motifs that direct miRNA trafficking by interaction with specific chaperone 
proteins(Bolukbasi et al. 2012; Villarroya-Beltri et al. 2013a). Although we did not find any 
globally significant motif overrepresented in exosomal miRNAs, we cannot rule out that 
individual miRNAs might undergo sequence-specific export.  miR-320 family members all 
contain the GGAG motif that has been proposed to serve as an exosomal targeting 
signal(Villarroya-Beltri et al. 2013a).  We found that members of the miR-320 family are 
preferentially enriched in exosomes independent of KRAS status; however, the GGAG sequence 
was not found in other miRNAs that are targeted to exosomes.  It has been reported that the 
biogenesis of miR-320 family members occurs by a non-canonical pathway that requires neither 
Drosha(Chong et al. 2010) nor XPO5(Xie et al. 2013).  Instead, the 5’ ends contain a 7-methyl 
guanosine cap that facilitates nuclear-cytoplasmic transport through XPO1(Xie et al. 2013).  
XPO1 is present in DKO-1, DKs-8 and DLD-1 exosomes as detected by mass 
spectrometry(Demory Beckler et al. 2012).  It will be interesting to investigate whether alternate 
processing pathways and associated biogenic machinery contribute to the heterogeneity of 
extracellular vesicle cargo and affect miRNA secretion.  
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  It was recently demonstrated that miRNAs in B-cell exosomes display enriched levels of 
nontemplate-directed 3’-uridylated miRNAs, while 3’-adenylated miRNA species are 
preferentially cell-enriched(Koppers-Lalic et al. 2014).  In certain contexts, the addition of 
nontemplated uridine residues to cognate miRNAs accelerates miRNA turnover(Baccarini et al. 
2011; Wei et al. 2012).  Thus, it is possible that the stability/half-life of a miRNA affects whether 
it is retained or secreted.  While the exact functional significance of 3’-end modifications of 
miRNAs detected in both cells and exosomes remains to be determined, it could be that 
differential export of “tagged” miRNAs could allow cells to export specific miRNAs.  However, 
the lack of any apparent motif upon global analysis of miRNAs enriched in exosomes, coupled to 
the finding that even untagged miRNAs are differentially exported, suggests multiple strategies 
for loading of miRNAs into extracellular vesicles, and that not all extracellular vesicles and 
exosomes contain identical cargo.  This further implies that different cell types secrete a 
heterogeneous population of vesicles.  Although the biological relevance of these findings 
remain to be determined, the specific sorting of miRNAs into exosomes may enable cancer cells 
to discard tumor suppressive miRNAs so as to increase their oncogenic potential, or perhaps 
modulate gene expression in neighboring and distant cells to promote tumorigenesis.  In support 
of this hypothesis, miR-100, which we found to be enriched in mutant KRAS exosomes, was 
found to down-regulate LGR5 in colorectal cancer cells and thereby inhibit migration and 
invasion of such cells(Zhou et al. 2014).  In this context, removal of miR-100 from the cell would 
be a tumor-promoting event.  
In other contexts, miR-100 can have contradictory activities, both inducing EMT by 
down-regulating E-cadherin through targeting SMARCA5, and inhibiting tumorigenicity by 
targeting HOXA1(D. Chen et al. 2014).  Thus, although miR-100 can function as a tumor 
suppressor under normal conditions, augmenting its levels, for example by extracellular vesicle 
uptake, could potentially promote EMT.  In this regard, the role of miR-100 in tumorigenesis 
would be two-fold, where its secretion in exosomes could function to maintain low intracellular 
levels within mutant cells, while inducing EMT in wild-type recipient cells.  Along these lines, 
miR-100 is part of the miR-125b/let-7a-2/miR-100 cluster that is transcribed and expressed 
coordinately (Emmrich et al. 2014).Interestingly, in malignant colonic tissues from individuals 
with CRC, miR-100 levels were significantly decreased while let-7a levels were strongly 
upregulated(Tarasov et al. 2014). Based on our finding that there is differential accumulation of 
41 
 
 
individual miRNAs within this cluster between mutant KRAS cells and exosomes, it will be 
interesting to determine whether cancer cells down-regulate specific miRNAs by active 
secretion, while simultaneously maintaining the levels of other miRNAs transcribed within the 
same cluster.   
 miRNAs are secreted from malignant breast epithelial cells after packaging into vesicles 
larger than conventional exosomes that are enriched in CD44, whose expression is linked to 
breast cancer metastasis(Palma et al. 2012).  Normal cells tend to release miRNAs in more 
homogenous types of exosomes, suggesting that malignant transformation may alter the 
formation of secreted vesicles that could alter miRNA export and lead to differences in exosome 
content and morphology(Palma et al. 2012; Melo et al. 2014).  In support of this, it was recently 
shown that in exosomes from breast cancer cells, CD43 mediates the accumulation of 
Dicer(Melo et al. 2014).  These exosomes also contain other RISC proteins and pre-miRNAs, 
indicating that miRNA processing can occur in exosomes.  These components were absent in 
exosomes derived from normal cells.  It remains to be determined whether components of the 
RISC loading complex assemble within endosomes before their secretion as exosomes, or by the 
fusion of exosomes containing heterogeneous cargo after they are secreted.  The observation that 
cells can selectively release miRNAs and also release a heterogeneous population of vesicles 
raises the possibility that differential release of miRNAs is associated with different classes of 
exosomes and microvesicles. 
 Recently, quantitative analysis of secreted miRNAs suggested that the levels of 
extracellular miRNAs are limited and raise the question as to how such levels can alter gene 
expression in recipient cells(Chevillet et al. 2014).  The results of our Transwell co-culture 
experiments are most consistent with extracellular transfer of specific miRNAs to alter 
expression of reporter constructs.  Nevertheless, the level of exosomal transfer that is needed to 
alter recipient cell gene expression in vivo remains an open question.  Our finding that mutant 
KRAS protein can be functionally transferred in exosomes indicates that the full effect of 
exosomes on recipient cells can be due to a combination of both RNA delivery and protein-based 
signaling(Higginbotham et al. 2011a).  This could include activation of Toll-like receptors with 
possible downstream effects following NFKB or MAPK cascades(Fabbri et al. 2012; X. Chen et 
al. 2013). The complexity of miR-100 function in the tumor microenvironment underscores this 
argument by its potential for inhibiting mTOR expression which is required for proliferation of 
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Apc-deficient tumors in mouse models(Faller et al. 2015).  In tumors where some cells have 
incurred activating mutations in KRAS, while others have not, miR-100 could accumulate in 
wild-type KRAS tumor cells through exosomal transfer, inhibiting mTOR and cell growth.  
Conversely miR-100 could be secreted from mutant KRAS cells giving them a growth advantage.  
In this way exosomal transfer of miRNAs might act to select for cells carrying specific tumor 
driver mutations. Our studies have direct implications for CRC and, together with other studies, 
indicate that delivery of exosomes to recipient cells can induce cell migration, inflammation, 
immune responses, angiogenesis, invasion, pre-metastatic niche formation, and 
metastasis(Kahlert and Kalluri 2013; Boelens et al. 2014; Melo et al. 2014). 
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Table 4. miRNAs enriched in cell* 
DKO-1 
hsa-miR-548u hsa-miR-16-1-3p hsa-miR-33a-3p hsa-miR-33a-5p 
hsa-miR-31-5p hsa-miR-181b-3p hsa-miR-450a-5p hsa-miR-424-5p 
hsa-miR-9-5p hsa-miR-219-5p hsa-miR-190a hsa-miR-573 
hsa-miR-30d-3p hsa-miR-204-5p hsa-miR-1226-3p hsa-miR-499a-5p 
hsa-miR-450b-5p hsa-miR-499b-3p hsa-miR-3662 hsa-miR-20a-3p 
hsa-miR-27b-5p hsa-miR-5701 hsa-miR-4677-3p hsa-let-7i-5p 
hsa-miR-331-3p hsa-miR-31-3p hsa-miR-651 hsa-miR-1306-5p 
hsa-miR-147b hsa-miR-3611 hsa-miR-1305 hsa-miR-148a-3p 
hsa-miR-27b-3p hsa-miR-1306-3p hsa-miR-374b-3p hsa-miR-1260b 
hsa-miR-3940-3p hsa-miR-200c-5p hsa-miR-548ar-3p 
    
DKs-8 
hsa-miR-132-5p hsa-miR-484 hsa-miR-374a-5p hsa-miR-1180 
hsa-miR-1307-3p hsa-miR-200a-5p hsa-miR-548o-3p hsa-miR-149-5p 
hsa-miR-3615 hsa-miR-100-5p hsa-miR-197-3p hsa-miR-378a-5p 
hsa-let-7a-3p   
    
DLD-1 
hsa-miR-141-3p hsa-miR-26b-5p hsa-miR-24-3p hsa-miR-3074-5p 
hsa-miR-15a-5p hsa-miR-27a-3p hsa-miR-3613-5p hsa-miR-30b-5p 
hsa-miR-29a-3p hsa-miR-301a-5p hsa-let-7i-3p hsa-miR-185-5p 
hsa-let-7g-5p hsa-miR-23b-3p hsa-miR-22-3p 
    
DKO-1 & DKs-8 
hsa-miR-141-5p hsa-miR-582-5p  
    
DKO-1 & DLD-1 
hsa-miR-556-3p hsa-miR-374a-3p hsa-miR-106b-5p hsa-miR-17-3p 
hsa-miR-24-1-5p hsa-miR-340-3p  
    
DLD-1 & DKs-8 
hsa-miR-24-2-5p hsa-miR-106a-5p hsa-miR-30e-5p hsa-miR-107 
hsa-miR-429 hsa-miR-98-5p hsa-miR-425-5p hsa-miR-140-5p 
hsa-miR-93-5p hsa-miR-210 hsa-miR-126-3p hsa-miR-194-5p 
hsa-miR-29b-3p hsa-miR-15b-5p hsa-miR-362-5p hsa-miR-27a-5p 
hsa-miR-454-3p hsa-miR-452-5p hsa-miR-196b-5p 
    
DKO-1, DLD-1 & DKs-8 
hsa-miR-32-5p hsa-miR-582-3p hsa-miR-542-3p hsa-miR-96-5p 
hsa-miR-101-3p hsa-miR-18a-5p hsa-miR-3529-3p hsa-miR-7-5p 
hsa-miR-19a-3p hsa-miR-142-3p hsa-miR-20a-5p hsa-miR-32-3p 
hsa-miR-130b-5p hsa-miR-1278 hsa-miR-7-1-3p hsa-miR-590-3p 
hsa-miR-4473 hsa-miR-17-5p hsa-miR-103a-3p hsa-miR-103b 
hsa-miR-19b-3p hsa-miR-340-5p hsa-miR-200a-3p hsa-miR-34a-5p 
hsa-miR-372   
 
*miRNAs differentially enriched in cells when comparing mean reads in exosomes versus cell. 
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Table 5. miRNAs enriched in exosomes * 
DKO-1 
hsa-miR-139-5p hsa-miR-3178 hsa-miR-151b hsa-miR-125b-1-3p 
hsa-miR-193b-3p hsa-miR-935 hsa-miR-130b-3p hsa-miR-628-3p 
hsa-miR-139-3p hsa-let-7d-3p hsa-miR-589-3p hsa-miR-4532 
hsa-miR-451a hsa-miR-6087 hsa-miR-151a-5p hsa-miR-940 
hsa-miR-222-3p hsa-miR-766-5p hsa-miR-505-5p hsa-miR-3187-3p 
hsa-miR-125a-3p hsa-miR-3679-5p hsa-miR-4436b-3p hsa-miR-4787-3p 
hsa-miR-2277-3p hsa-miR-361-5p hsa-miR-1293 hsa-miR-3183 
hsa-miR-3162-5p hsa-miR-642a-3p hsa-miR-642b-5p hsa-miR-197-5p 
hsa-miR-324-3p hsa-miR-145-3p hsa-miR-3182 hsa-miR-3127-3p 
hsa-miR-3127-5p hsa-miR-4728-3p hsa-miR-3184-5p hsa-miR-125b-5p 
hsa-miR-186-5p hsa-miR-1 hsa-miR-100-5p hsa-miR-423-3p 
hsa-miR-766-3p hsa-miR-4753-5p hsa-miR-145-5p hsa-miR-4724-5p 
hsa-miR-373-3p hsa-miR-223-5p hsa-miR-1307-5p hsa-miR-1914-3p 
hsa-miR-3121-3p hsa-miR-3613-3p hsa-miR-205-5p hsa-miR-98-3p 
hsa-miR-23a-3p hsa-miR-3124-5p hsa-miR-3656 hsa-miR-3918 
hsa-miR-4449 hsa-miR-378c hsa-miR-3138 hsa-miR-1910 
hsa-miR-3174 hsa-miR-4466 hsa-miR-3679-3p hsa-miR-3200-5p 
hsa-miR-6511b-5p hsa-miR-1247-5p hsa-miR-22-3p hsa-miR-877-5p 
hsa-miR-4687-3p hsa-miR-1292-5p hsa-miR-181c-5p hsa-miR-6131 
hsa-miR-6513-5p hsa-miR-3661 hsa-miR-132-3p hsa-miR-214-3p 
hsa-miR-574-3p hsa-miR-3190-3p hsa-miR-326 hsa-miR-3191-5p 
hsa-miR-3198 hsa-miR-3928 hsa-miR-629-3p hsa-miR-4489 
hsa-miR-4700-5p hsa-miR-5006-5p hsa-miR-5088 hsa-miR-2110 
hsa-miR-3911 hsa-miR-3146  
    
DKs-8 
hsa-miR-1224-5p hsa-let-7b-5p hsa-miR-155-5p hsa-let-7c 
hsa-let-7a-5p hsa-miR-146b-5p hsa-miR-4647 hsa-miR-4494 
hsa-miR-711 hsa-miR-1263  
    
DLD-1 
hsa-miR-1226-5p hsa-miR-4745-5p hsa-miR-4435 hsa-miR-939-5p 
hsa-miR-409-3p hsa-miR-1304-3p  
    
DKO-1 & DKs-8 
hsa-miR-146a-5p hsa-miR-4508 hsa-miR-224-5p hsa-miR-4429 
hsa-miR-222-5p hsa-miR-629-5p hsa-miR-4492 hsa-miR-3653 
hsa-miR-320a hsa-miR-1290 hsa-miR-1262 hsa-miR-5010-5p 
hsa-miR-204-3p hsa-miR-4461 hsa-miR-5187-5p 
    
DKO-1 & DLD-1 
hsa-miR-483-5p hsa-miR-4658 hsa-miR-4758-5p hsa-miR-492 
hsa-miR-5001-5p hsa-miR-371a-5p hsa-miR-1323 hsa-miR-371b-3p 
hsa-miR-501-3p hsa-miR-4446-3p hsa-miR-6511a-5p hsa-miR-30a-3p 
hsa-miR-4727-3p   
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DLD-1 & DKs-8 
hsa-miR-28-3p hsa-miR-3934-5p  
    
DKO-1, DLD-1 & DKs-8 
hsa-miR-658 hsa-miR-320d hsa-miR-4792 hsa-miR-1246 
hsa-miR-320e hsa-miR-4516 hsa-miR-320b hsa-miR-4488 
hsa-miR-1291 hsa-miR-320c hsa-miR-4634 hsa-miR-3605-5p 
hsa-miR-4741 hsa-miR-3591-3p hsa-miR-122-5p hsa-miR-486-3p 
hsa-miR-184 hsa-miR-223-3p hsa-miR-3651 hsa-miR-486-5p 
hsa-miR-3180 hsa-miR-3180-3p hsa-miR-3168 hsa-miR-4497 
hsa-miR-423-5p hsa-miR-3184-3p hsa-miR-150-5p hsa-miR-664a-5p 
hsa-miR-182-5p   
    
 
*miRNAs differentially enriched in exosomes when comparing mean reads in exosomes versus cell. 
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2.5 Methods 
Exosome isolation 
Exosomes were isolated from conditioned medium of DKO-1, Dks-8, and DLD-1 cells as 
previously described, with slight modification[15].  Briefly, cells were cultured in DMEM 
supplemented with 10% bovine growth serum until 80% confluent.  The cells were then washed 
3 times with PBS and cultured for 24 hr in serum-free medium.  The medium was collected and 
replaced with ionomycin-containing medium for 1 hr, after which ionomycin-containing medium 
was collected and pooled with the previously collected serum-free medium.  Pooled media was 
centrifuged for 10 min at 300 X g to remove cellular debris, and the resulting supernatant was 
then filtered through a 0.22-mm polyethersulfone filter (Nalgene, Rochester, NY, USA) to 
reduce microparticle contamination.  The filtrate was concentrated ~300-fold with a 100,000 
molecular-weight cutoff centrifugal concentrator (Millipore, Darmstadt, Germany).  The 
concentrate was then subjected to high-speed centrifugation at 150,000 X g for 2 hr.  The 
resulting exosome-enriched pellet was resuspended in PBS containing 25 mM HEPES (pH 7.2) 
and washed by centrifuging again at 150,000 X g for 3 hr.  The wash steps were repeated a 
minimum of 3 times until no trace of phenol-red was detected.  The resulting pellet was 
resuspended in PBS containing 25 mM HEPES (pH 7.2) and protein concentrations were 
determined with a MicroBCA kit (Pierce/Thermo, Rockford, IL, USA).  The number of 
exosomes per µg of protein was determined by means of nanoparticle tracking analysis 
(NanoSight, Wiltshire, UK).  Analysis was performed on three independent preparations of 
exosomes. 
 
RNA purification 
Total RNA from exosomes and cells was isolated using TRIzol (Life Technologies/Thermo).  In 
the case of exosomal RNA isolation TRIzol was incubated with 100 ul or less of concentrated 
exosomes for an extended 15 min incubation prior to chloroform extraction.  RNA pellets were 
resuspended in 60 µl of RNase-free water and were then re-purified using the miRNeasy kit 
(Qiagen Inc., Valencia, CA, USA).  Final RNAs were eluted with two rounds of 30 ul water 
extraction. 
 
47 
 
 
miRNA library preparation and sequencing 
Total RNA from each sample was used for small RNA library preparation using NEBNext Small 
RNA Library Prep Set from Illumina (New England BioLabs Inc., Ipswich, MA, USA).  Briefly, 
3` adapters were ligated to total input RNA followed by hybridization of multiplex SR RT 
primers and ligation of multiplex 5’ SR adapters.  Reverse transcription (RT) was performed 
using ProtoScript II RT for 1 hr at 50°C.  Immediately after RT reactions, PCR amplification 
was performed for 15 cycles using LongAmp Taq 2X master mix.  Illumina-indexed primers 
were added to uniquely barcode each sample.  Post-PCR material was purified using QIAquick 
PCR purification kits (Qiagen Inc.).  Post-PCR yield and concentration of the prepared libraries 
were assessed using Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, California, CA, USA) and 
DNA 1000 chip on Agilent 2100 Bioanalyzer (Applied Biosystems, Carlsbad, CA, USA), 
respectively.  Size selection of small RNA with a target size range of approximately 146-148 bp 
was performed using 3% dye free agarose gel cassettes on a Pippin Prep instrument (Sage 
Science Inc., Beverly, MA, USA).  Post-size selection yield and concentration of libraries were 
assessed using Qubit 2.0 Fluorometer and DNA high sensitivity chip on an Agilent 2100 
Bioanalyzer, respectively.  Accurate quantification for sequencing applications was performed 
using qPCR-based KAPA Biosystems Library Quantification kits (Kapa Biosystems, Inc., 
Woburn, MA, USA).  Each library was diluted to a final concentration of 1.25 nM and pooled in 
equimolar ratios prior to clustering.  Cluster generation was carried out on a cBot v8.0 using 
Illumina’s Truseq Single Read (SR) Cluster Kit v3.0.  Single End (SE) sequencing was 
performed to generate at least 15 million reads per sample on an Illumina HiSeq2000 using a 50-
cycleTruSeq SBSHSv3 reagent kit.  Clustered flow cells were sequenced for 56 cycles, 
consisting of a 50-cycle read, followed by a 6-cycle index read.  Image analysis and base calling 
was performed using the standard Illumina pipeline consisting of Real Time Analysis (RTA) 
version v1.17 and demultiplexed using bcl2fastq converter with default settings. 
 
Mapping of RNA reads 
Read sequence quality checks were performed by FastQC  (Babraham Bioinformatics 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  Adapters from the 3’ ends of reads 
were trimmed using Cutadpt with a maximum allowed error rate of 0.1.  Reads shorter than 15 
nucleotides in length were excluded from further analysis.  Reads were mapped to the human 
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genome hg19 using Bowtie version 1.1.1.  Mapped reads were annotated using ncPRO-seq based 
on miRbase, Rfam and RepeatMasker (http://www.repeatmasker.org/) and expression levels 
were quantified based on read counts.  Mature miRNA annotation was extended 2 bp in both 
upstream and downstream regions to accommodate inaccurate processing of precursor miRNAs.  
Reads with multiple mapping locations were weighted by the number of mapping locations.  
 
Principal Component analysis 
DESeq Version 1.16.0 was used to perform Principal Component analyses. 
 
Enrichment analysis 
Differential expression was analyzed using DESeq Version 1.16.0.  Negative binomial 
distribution was used to compare miRNA abundance between cells versus exosomes and wild 
type versus mutant KRAS status.  The trimmed mean of M values (TMM) method was used for 
normalization.  Differential expression was determined based on log2 fold change (log2 fold 
change) and False Discovery Rate (FDR) with |log2 Fold Change| >= 1 and FDR <= 0.001. 
 
Trimming and tailing 
Trimming and tailing analysis was based on miRBase annotation.  Only high confidence 
miRNAs (544) and corresponding hairpin sequences were used.  Bowtie version 1.1.1 with 0 
mismatch was used for mapping. miRNA reads were first mapped to hairpin sequences with 
unmapped reads then mapped to the human genome hg19.  Remaining reads were trimmed 1 bp 
form the 3’ end and remapped to hairpin sequences.  The remapping process was repeated 10 
times.  Finally, all mapped reads were collected for further analysis. 
 
qRT/PCR  
Taqman small RNA assays (Life Technologies) (individual assay numbers are listed below) were 
performed for indicated miRNAs on cellular and exosomal RNA samples.  Briefly, 10 ng of total 
RNA was used per individual RT reactions; 0.67 µl of the resultant cDNA was used in 10 µl 
qPCR reactions.  qPCR reactions were conducted in 96-well plates on a Bio-Rad CFX96 
instrument.  All C(t) values were ≤ 30.  Triplicate C(t) values were averaged and normalized to 
U6 snRNA.  Fold-changes were calculated using the ΔΔC(t) method, where: Δ=C(t)miRNA-C(t)U6 
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snRNA, and ΔΔC(t)= ΔC(t)exo-ΔC(t)cell, and FC=2
-ΔΔC(t)
.  Analysis was performed on three 
independent cell and exosomal RNA samples.  Taqman probe #: U6 snRNA: 001973; hsa-let-7a-
5p: 000377; hsa-miR-100-5p: 000437; hsa-miR-320b: 002844; hsa-miR-320a: 002277. 
 
Generation of miRNA standard curves 
RNase-free, HPLC-purified 5’-phosphorylated miRNA oligoribonucleotides were synthesized 
(Integrated DNA Technologies) for human miR-100-5p (5’-phospho-
AACCCGUAGAUCCGAACUUGUG-OH-3’) and cel-miR-39-3p (5’-phospho-
UCACCGGGUGUAAAUCAGCUUG-OH-3’).  Stock solutions of 10μM synthetic 
oligonucleotide in RNase-free and DNase-free water were prepared according to the 
concentrations and sample purity quoted by the manufacturer (based on spectrophotometry 
analysis).  Nine 2-fold dilution series beginning with 50pM synthetic oligonucleotide were used 
in 10ul RT reactions (Taqman small RNA assays) and qPCR was performed.  Each dilution was 
performed in triplicate from three independent experiments.  Linear regression was used to 
determine mean C(t) values plotted against log(miRNA copies/ul). 
 
miRNA in situ hybridizations and ceramide dependence 
Cells were plated in 6-well plates containing coverslips at a density of ~2.5x10
5
 cells and 
cultured in DMEM supplemented with 10% bovine growth serum for 24 hr.  The cells were then 
washed 3 times with PBS and cultured for 24 hr in serum-free medium containing either 5 uM 
GW4869 (Cayman Chemicals # 13127, Ann Arbor, MI, USA) or DMSO.  Medium was removed 
and cells were washed 3 times with PBS and fixed with 4% PFA for ~15 min at room 
temperature. After, cells were washed 3 times in DEPC-treated PBS and permeabilized in 70% 
ethanol for ~4 hr at 4°C, and rehydrated in DEPC-treated PBS for 5 min.  Pre-hybridization was 
performed in hybridization buffer (25% formamide, 0.05 M EDTA, 4X SSC, 10% dextran 
sulfate, 1X Denhardts solution 1mg/ml E.coli tRNA) in a humidified chamber at 60°C for 60 
min.  Hybridization buffer was removed and replaced with 10 nM of probe (probe numbers are 
listed below) diluted in hybridization buffer and incubated at either 55°C  (miR-100 and miR-
10b) or 57°C for scrambled and U6 probes for 2 hr.  Coverslips were then washed in series with 
pre-heated SSC at 37°C as follows: 4X SSC briefly, 2X SSC for 30 min., 1x SSC for 30 min, and 
0.1x SSC for 20 min.  miRNA detection was conducted using Tyramide Signal Amplification 
50 
 
 
(TSA) (Perkin Elmer, # NEL741001KT, Waltham, MA, USA).  Briefly, coverslips were blocked 
in blocking buffer (0.1 M TRIS-HCl, pH 7.5, 0.15 M NaCl, 0.5% Blocking Reagent [Roche, 
#11096176001, Basel, Switzerland]) at 4°C overnight.  Blocking buffer was replaced with anti-
DIG-POD (Roche, # 11207733910) diluted 1:100 in blocking buffer and incubated for 60 min.  
Coverslips were washed 3 times, 5 min per wash, in wash buffer (0.1 M TRIS-HCl, pH 7.5, 0.15 
M NaCl, 0.5% Saponin) followed by incubation with 1X Fluorescein diluted in 1X amplification 
reagent for 5 min.  Fluorescent coverslips were then washed 2 times, 5 min per wash, in wash 
buffer.  To preserve fluorescent signals, coverslips were fixed with 2% PFA containing 2% BSA 
in 1X PBS for 15 min.  After fixation, coverslips were washed 2 times, 5 min per wash, in wash 
buffer, followed by a final wash in 1X PBS for 5 min.  Coverslips were then mounted in Prolong 
Gold (Life Technologies) and visualized on a Zeiss LSM510 at 63X objective.  3’-DIG labeled 
probes for in situ hybridizations- U6 snRNA: 99002-05; Scramble: 99004-05; miR-10b-5p: 
38486-05; miR-100-5p: 18009-05 (Exiqon, Woburn, MA, USA). 
 
Co-culture and luciferase reporter assays   
Recipient cells were plated in 6-well plates at a density of ~2.5x10
5
 cells and cultured in DMEM 
supplemented with 10% bovine growth serum for 24 hr.  Media was replaced and cells were co-
transfected (Promega, E2311, Madison, WI, USA) with 1.5 ug of Luc-reporter plasmid and 1.5 
ug β-gal plasmid DNA/well.  Donor cells were plated in 0.4 um polyester membrane Transwell 
filters (Corning, 3450, Corning, NY, USA) at ~2.5x10
5
 cells/well for 24 hrs.  Media from donor 
Transwells and recipient 6-well plates were removed and replaced with DMEM without FBS.  
Co-culture of donor and recipient cells were conducted for either 24 or 48 hrs before recipient 
cells were harvested.  Lysates were prepared in 1X Reporter lysis buffer (Promega, E2510) and 
luciferase assays were performed according to the manufacturer’s protocol (Promega, E2510).  
β-Gal expression was simultaneously determined from the lysates according to the 
manufacturer’s protocol (Promega, E2000).  Differences in transfection efficiency were 
accounted for by normalizing Luc expression to β-Gal expression (Luc/β-Gal).  All assays were 
performed on 3 biological replicates, each with 3 technical replicates.  
 
Antagomir treatment 
Donor cells were plated in 0.4 μm polyester membrane Transwell filters (Corning, 3450, 
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Corning, NY, USA) at ~1.4x10
4
 cells/well for 24 hrs.  Medum was replaced and donor cells were 
transfected with either miR-100 hairpin antagomirs (# IH-300517-05, GE Life Sciences) or 
negative control hairpin antagomirs corresponding to cel-miR-67 (# IN-001005-01, GE Life 
Sciences) to produce a final concentration of 100 nM of antagomir for 24 hrs.  Medium from 
donor Transwells and recipient 6-well plates was removed and replaced with DMEM without 
FBS.  Co-culture of donor and recipient cells was conducted for 24 hrs before recipient cells 
were harvested for RNA isolation. 
 
Plasmid construction   
For the pLuc-mTOR construct, the 3’UTR of mTOR was PCR amplified (primer sequences in 
Supplemental Table 5) from genomic DNA isolated from DKs-8 cells.  The amplicon was cloned 
into pMiR-Report (Life Technologies) via SpeI/HinDIII restriction sites.  Mutation of miR-100 
binding sites in mTOR 3UTR (MS) was performed on pLuc-mTOR using forward or reverse 
primers targeting either all three MRE’s, or MRE 2 & 3 with QuikChange Lightning Multi-Site 
Directed Mutagenesis (Agilent, Santa Clara, CA, USA) according to manufacturer’s protocol.  
To create the reporter construct containing three miR-100 perfect sites (miR-100-PT), 
oligonucleotides were annealed to produce a synthetic fragment containing the perfect sites with 
CTAGT and AGCTT overhangs. The fragment was cloned into pMiR-report via SpeI/HinDIII 
restriction sites. All plasmids were sequence verified (GeneWiz, South Plainfield, NJ, USA). 
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Chapter 3 
 
 
Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be 
transferred to exosomes
2 
 
3.1. Abstract 
Recent studies have shown that circular RNAs (circRNAs) are abundant, widely expressed in 
mammals, and can display cell-type specific expression. However, how production of circRNAs 
is regulated and their precise biological function remains largely unknown. To study how 
circRNAs might be regulated during colorectal cancer progression, we used three isogenic colon 
cancer cell lines that differ only in KRAS mutation status. Cellular RNAs from the parental DLD-
1 cells that contain both wild-type and G13D mutant KRAS alleles and isogenically-matched 
derivative cell lines, DKO-1 (mutant KRAS allele only) and DKs-8 (wild-type KRAS allele only) 
were analyzed using RNA-Seq. We developed a bioinformatics pipeline to identify and evaluate 
circRNA candidates from RNA-Seq data. Hundreds of high-quality circRNA candidates were 
identified in each cell line. Remarkably, circRNAs were significantly down-regulated at a global 
level in DLD-1 and DKO-1 cells compared to DKs-8 cells, indicating a widespread effect of 
mutant KRAS on circRNA abundance. This finding was confirmed in two independent colon 
cancer cell lines HCT116 (KRAS mutant) and HKe3 (KRAS WT). In all three cell lines, 
circRNAs were also found in secreted extracellular-vesicles, and circRNAs were more abundant 
in exosomes than cells. Our results suggest that circRNAs may serve as promising cancer 
biomarkers.  
 
 
 
 
 
 
_____________________________________________________________________________________________
2. Yongchao Dou, Diana J. Cha, Jeffrey L. Franklin, James N. Higginbotham, Dennis K Jeppesen, Alissa M. 
Weaver, Nripesh Prasad, Shawn Levy, Robert J. Coffey, James G. Patton & Bing Zhang. “Circular RNAs are down-
regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.” Sci. Rep. 6, 37982; doi: 
10.1038/srep37982 (2016).  
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3.2. Introduction 
Circular RNAs (circRNAs) were first reported more than 30 years ago(Cocquerelle et al. 
1993; Saad et al. 1992; Nigro et al. 1991), but had long been perceived as occasional RNA 
splicing errors until recent genome-wide analyses powered by next generation sequencing (NGS) 
technologies have shown these are bona fide RNA species. Studies during the past several years 
have identified a large number of exonic and intronic circRNAs across the eukaryotic lineage, 
including human, mouse, zebrafish, worms, fungi, and plants(Memczak et al. 2013; P. L. Wang 
et al. 2014). Based on the assumption that the abundance of circRNAs is much lower than that of 
linear RNAs, early studies typically use RNase R, a magnesium-dependent 3′ to 5′ 
exoribonuclease, to deplete linear RNAs before sequencing(Cheng and Deutscher 2005). 
However, recent work showed that the abundance of circRNAs is similar to or higher than that of 
linear transcripts for about one in eight human genes(Jeck et al. 2013), which can be partially 
explained by higher cellular stability and longer half-life of circRNAs compared to linear 
mRNAs(Jeck and Sharpless 2014). The observed high abundance of circRNAs suggests that 
RNase R treatment is likely to be unnecessary in NGS-based analysis of circRNAs, consistent 
with the identification of 7112 circRNA candidates from non-poly(A)-selected libraries 
generated by the ENCODE project(Guo et al. 2014; Consortium 2004). It is now clear that 
circRNAs are evolutionarily conserved, exhibit cell-specific expression patterns, and are 
regulated independent of their linear transcripts(Jeck et al. 2013; Salzman et al. 2013). For 
example, circRNAs are enriched in brain and accumulate to the highest levels in the aging 
central nervous system(Westholm et al. 2014; Rybak-Wolf et al. 2015). Recent studies also 
showed that circRNAs can be transferred to human exosomes(Y. Li et al. 2015), where they are 
enriched and stable. These findings suggest that circRNAs are prevalent, abundant, and 
potentially functional. 
Knowledge about the general sequence features, biogenesis, and putative functions of 
circRNAs, especially exonic circRNAs, has gradually accumulated(Jeck and Sharpless 2014). 
Because both circRNAs and linear RNAs are spliced from pre-mRNAs, the competition between 
circularization and linear splicing may play a role in the regulation of gene expression(Ashwal-
Fluss et al. 2014). Moreover, introns between exons may be retained when exons are 
circularized(Z. Li et al. 2015). Circularization of exonic circRNAs typically involves the 
canonical GU-AG splice site pairs(Black 2003) and can contain one or multiple exons. On 
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average, single-exon circRNAs form with exons that are three times longer than non-circularized 
exons(Jeck and Sharpless 2014). Exon circularization is promoted by pairing of reverse 
complementary sequences within introns bracketing circRNAs; reverse complimentary 
sequences are primarily Alu repeats(X.-O. Zhang et al. 2014; D. Liang and Wilusz 2014; A. 
Ivanov et al. 2015). Two possible mechanisms for the formation of exonic circRNAs have been 
proposed, and both involve the canonical spliceosome(Jeck and Sharpless 2014). Two circRNAs 
in mammals have been shown to function as miRNA sponges(Memczak et al. 2013), but 
significant enrichment of miRNA binding sites was not found for the majority of circRNA 
candidates(Guo et al. 2014; Consortium 2004). 
Although other non-coding RNAs have been shown to play critical roles in cancer, the 
association between circRNAs and cancer is largely unknown(Hansen, Kjems, and Damgaard 
2013; Bachmayr-Heyda et al. 2015). In this study, we performed deep RNA-Seq analysis of 
rRNA-depleted total RNA libraries to characterize circRNA expression in three isogenically-
matched human colon cancer cell lines that differ only in the mutation status of 
the KRAS oncogene. The parental DLD-1 cells contain both wild-type and G13D 
mutantKRAS alleles, whereas the isogenically-matched derivative cell lines DKO-1 and DKs-8 
contain only a mutant KRAS and a wild-type KRAS allele, respectively.  
KRAS mutations occur in approximately 34–45% of colon cancers(Vogelstein et al. 
1988) and have been associated with a wide range of tumor-promoting effects(Velho and Haigis 
2011). We developed an integrated bioinformatics pipeline to identify, confirm and annotate 
circRNAs based on RNA-Seq data. Using the pipeline, we studied both cellular and exosomal 
circRNAs in the three cell lines, with confirmation of altered circRNAs in a second set of 
isogenically matched cell lines. To our knowledge, this is the first report describing the impact of 
a well-established oncogene on the abundance of circRNAs. 
 
3.3. Results 
 
Bioinformatics pipeline 
Exonic circRNAs largely result from back-spliced exons, in which splice junctions are 
formed by an upstream 5′ splice acceptor and a downstream 3′ splice donor. Back-splice reads 
mapping to such junctions are the most important indicator for circRNAs that can be gleaned 
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from RNA-Seq data(Memczak et al. 2013; Jeck and Sharpless 2014; Westcott et al. 2014; X.-O. 
Zhang et al. 2014; Hansen et al. 2013). Similar to the existing pipeline used by Memczak et 
al.(Memczak et al. 2013), our pipeline (Fig. 10A) uses the presence of back-splice reads to 
identify exonic circRNA candidates. However, multiple mapping positions are allowed when 
mapping anchors in our pipeline. Find-circ only reports a random mapping position and may 
therefore miss some circRNAs (false negatives). Moreover, because one read may be considered 
as a back-splicing candidate at one position or a linear gapped mapping at another position, find-
circ may also introduce false positives.  Thus, allowing multiple mapping positions in our 
pipeline may help reduce both false positives and false negatives. Briefly, one paired-end read 
was used as two single-end reads for mapping to the genome. Mappable reads were discarded 
because back-splice reads cannot be mapped to the genome directly. The 5′ and 3′ termini of 
unmapped reads were then extracted as anchors, which were aligned to the genome 
independently with multiple mapping allowed. Because multiple mapping is allowed, all possible 
pairs of anchor alignments were evaluated. If any of these pairs correspond to a normal linear 
gapped mapping, the read was discarded. For the remaining reads, all the possible extensions that 
could be extended to reconstruct the original read with a maximum of two mismatches were 
further considered. Then we will search the GU/AC splice sites for each extension. If any 
extensions with the GU/AC splice sites, the read was considered as with GU/AC splice sites. 
Extended alignments flanked by GU/AG splice sites were used to define a back-splice read. 
Contamination from other biological sources may affect both the identification and 
quantification of circRNAs. To check possible contaminations from bacteria and viruses, we 
built a database with all bacterial and viral sequences and blasted all back-splicing mates against 
the database. For cellular RNAs, 99.6% to 99.8% of the mates had no hits to the database and 
none of them had a hit with two or less mismatches. For exosomal RNAs, 91.8% to 99.4% of the 
mates had no hits to the database and only a few had a hit with two or less mismatches. Next, all 
back-splicing mates were mapped to the bovine genome(Elsik et al. 2016) both linearly and 
using the back-splicing detection algorithm. The linear mapping percentages were close to 0 for 
all samples, and no more than 2.2% of the back-splicing mates could be back-splicing-mapped to 
the bovine genome. These results show that the vast majority of the identified circular RNAs are 
not from bacterial and viral contamination and the potential contamination from the bovine 
sources is very limited. We discarded all back-splicing reads that can be mapped to bacterial, 
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viral, or bovine genomes from downstream analysis to avoid any influence from possible 
contamination. 
 
 
 
 
 
 
 
 
Figure 10: Bioinformatics pipeline and analysis of cell circRNAs (A) Computational pipeline. (B–D) 
Pearson Correlation analysis between cell replicates for DKs-8, DLD-1, and DKO-1 colorectal cell lines, 
respectively. (E) Distribution of percentages of back-splice mates with corresponding mates that can be 
mapped (PCMM) for each sample. 
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Identification of circRNA candidates in colorectal cancer cells 
We prepared cellular RNA libraries from the three isogenic-KRAS CRC cell lines, each 
with two biological replicates. RNase R treatment was not applied during library construction. 
 Sequence fragments supported by two or more remaining back-splice reads were 
considered as circRNA candidates, and those supported by ten or more back-splice reads were 
considered as high quality candidates. Finally, circRNA candidates with sequence fragment 
lengths between 100 and 1000,000 bp were reported by the pipeline. 
Sequencing was performed at high depth, with ~100 million reads per sample. Applying 
the above-described pipeline to cellular RNAs from the three cell lines identified thousands of 
circRNA candidates and hundreds of high quality circRNA candidates in each biological 
replicate (Table 6). Among the 1620 high quality candidates detected in our study, 1395 (86.1%) 
were found in the circBase database(Glažar, Papavasileiou, and Rajewsky 2014). 
 
Table 6: Identification of circRNA candidates in the three cell lines . 
Read type Samples 
DKs-8.1 DKs-8.2 DLD-1.1 DLD-1.2 DKO-1.1 DKO-1.2 
Paired-end reads 88746986 111215656 100025762 97930613 107392430 91024681 
Back-splice reads 65319 80701 47941 44717 40657 37403 
circRNA candidates 11061 13565 8771 8182 7348 6827 
High quality 
candidates 
932 1211 651 571 488 428 
Host genes 676 866 509 455 392 342 
Genes with >1 high 
quality candidates 
158 192 87 72 57 53 
. 
To assess the reproducibility of the data, we generated scatter plots comparing the back-
splice read counts of individual circRNAs from replicates of the three cell lines (Fig. 10B–D). 
As shown, the vast majority of all candidates were supported by consistent identification of 
back-splice reads in all replicates. Person’s correlations between replicates were 0.99, 0.93, and 
0.94 for DKs-8, DLD-1, and DKO-1, respectively. These scatter plots show circRNA candidates 
with higher read counts are closer to the diagonal, suggesting that reproducibility tended to be 
higher for circRNA candidates with high back-splice read counts. Therefore, our downstream 
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analyses focused only on high quality candidates with at least ten back-splice reads. 
To further evaluate the reliability of the identified circRNA candidates, we leveraged the 
paired end information. If one mate of a paired end read mapped to a back-splice junction (Mate 
a), the corresponding mate could be mapped to the candidate circRNA sequence either within the 
circle (Mate b’) or crossing the back-splice junction (Mate b). For each high quality candidate, 
we calculated the Percentage of back-splice mates with Corresponding Mates that can be mapped 
to the candidate circRNA sequence (PCMM), i.e. the percentage of properly paired back-splice 
mates. As shown in Fig. 8E, the median percentages ranged from 88.2% to 90.0% across the six 
samples, suggesting high reliability of these circRNA candidates. We also tested RNase R 
resistance of circRNAs in the DKO-1 and DKs-8 cell lines with the top four most abundant 
circRNAs. As shown in Figure 11, these circRNAs were enriched by RNase R (R+) treatment 
compared to mock treated controls (R−). Thus circRNAs are resisted to RNase R treatment. 
Taken together, these results suggest that a large number of circRNAs can be reliably and 
reproducibly identified and quantified in the three cell lines. 
 
 
Down-regulation of circRNAs in KRAS mutant cells 
To test whether the expression levels of circRNAs are regulated by KRAS, we compared 
the levels of circular RNA candidates between the mutant and wild-type KRAS cell lines. 
circRNAs were globally down-regulated in the mutant KRAS DKO-1 (Fig. 10A) and DLD-1 
(Fig. 10B) cell lines compared to the wild-type KRAS DKs-8 cell line. Specifically, 443 and 305 
Figure 11. Enrichment after RNase R treatment. qRT-PCR was performed on RNA isolated from either 
DKs-8 cells (blue) or DKO-1 cells (red) treated with or without RNase R. RNase R (R+) treatment enriches 
for circRNA species compared to mock treated RNA samples. This enrichent is greater in DKs-8 samples 
compared to DKO-1  (orange) samples. 
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circRNAs were significantly down-regulated in DKO-1 and DLD-1 cells, respectively (False 
Discovery Rate [FDR] < 0.01 and Fold Change [FC] >2). In contrast, only 5 and 13 circRNAs 
were significantly up-regulated in DKO-1 and DLD-1 cells, respectively. Among the top ten 
most abundant circRNAs in distinct genes, seven were significantly down-regulated in DKO-1 
cells and five of them were also significantly down-regulated in DLD-1 cells (Table 7). These 
results suggest that circRNAs are down-regulated in KRAS mutant cells at a global level. 
 
Table 7. Top10 most abundant circRNAs in distinct genes in DKs-8  
 
We next sought to determine whether circRNA down-regulation was due to down-
regulation of corresponding host genes. Figure 12 shows a direct comparison of the differential 
expression results for circRNAs and their host genes between each of the two mutant cell lines 
and the wild-type cell line. While the log-fold changes of the host genes exhibited a symmetrical 
distribution around 0, the log-fold changes of circRNAs were negatively shifted toward 
decreased abundance in mutant KRAS cell lines. The correlations between log-fold changes of 
circRNAs and host genes were 0.19 and 0.16, respectively, for the two comparisons. Using the 
most abundant circRNA candidate circRNA chr4:187627717-187630999 as an example, we 
found that this circRNA was down regulated by 6.6- and 5.3-fold in DLD-1 and DKO-1 cells, 
respectively compared to DKs-8 cells. In contrast, the host gene FAT1 was only down-regulated 
by 1.7- and 1.8-fold, respectively. These data suggest that circRNAs can be regulated 
independently of their corresponding host genes. 
  DLD-1/DKs-8 DKO-1/DKs-8 
Log2FC FDR Log2FC FDR 
chr4:187627717-187630999 FAT1 −2.71 0 −2.41 2.01E-267 
chr11:33307959-33309057 HIPK3 −0.81 1.26E-22 −1.07 1.40E-35 
chr14:32559708-32563592 ARHGAP5 −1.12 2.37E-34 −1.10 2.67E-32 
chr1:117944808-117963271 MAN1A2 −1.27 1.52E-25 −1.59 9.14E-36 
chr5:95091100-95099324 RHOBTB3 −1.00 1.97E-16 −1.54 4.30E-32 
chr2:55209651-55214834 RTN4 −1.81 2.69E-33 −2.04 1.93E-39 
chr17:20107646-20109225 SPECC1 −0.45 5.15E-04 −0.94 4.83E-12 
chr4:144464662-144465125 SMARCA5 −0.81 2.43E-09 −1.07 1.32E-14 
chr4:25789846-25804084 SEL1L3 −0.07 9.05E-01 −0.17 3.72E-01 
chr20:30954187-30956926 ASXL1 −0.50 9.78E-04 −0.66 1.68E-05 
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Figure 12. Differential expression analysis for cellular circRNAs. (A,B) circRNA differential expression 
analysis between mutant and wild-type KRAS cells. (C,D) Differential expression results for circRNAs and 
their host genes. Histograms of each gene and corresponding circRNAs log2FCs are shown above the X and Y-
axes, respectively. (E) qRT-PCR results for seven selected circRNAs between mutant and wild-type cells. (F) 
qRT-PCR results for host genes of selected circRNAs. (G) qRT-PCR results for seven selected circRNAs 
between HCT116 and HKe3 cells. (H) qRT-PCR results for host genes between HCT116 and HKe3 cells. 
(Two-tailed, paired t-test was used for the analysis. *denote p values ≤ 0.1 and **≤0.05).  
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To validate our findings, we performed qRT-PCR analysis for seven out of the ten most 
abundant circRNA candidates. As shown in Fig. 12E, all were confirmed by qRT-PCR and six 
out of the seven circRNA candidates were significantly down-regulated in at least one mutant 
cell line compared with the wild-type cell line (two-tailed, paired t-tests was used for the 
analysis, where *are p values ≤ 0.1 and **≤0.05). As a comparison, Fig. 12F shows different 
trends for the host genes of these circRNAs. These results further confirm our finding that 
circRNAs are down-regulated in mutant KRAS cells and that the regulation of circRNAs can 
occur independent of their host genes. 
To further strengthen our conclusion, we performed additional experiments using another 
pair of isogenically-matched human colon cancer cell lines, HCT116 and HKe3. Derived from a 
completely different cancer, HCT116 harbors mutant G13D KRAS while its clonal derivative 
HKe3 contains wild-type KRAS(Senji Shirasawa et al. 1993). Consistent with our previous 
results, all seven circRNAs assayed were down regulated in the HCT116 cells compared to the 
HKe3 cell line as shown in Fig. 12G. Among them, circFAT1 was significantly down-regulated 
in the mutantKRAS cell line (HCT116). Furthermore, the host genes for these candidates were 
not significantly differentially expressed between HCT116 and HKe3 cell lines (Fig. 12H). 
These results support our finding that circRNAs are down-regulated in mutant KRAS cells and 
that the regulation of circRNAs can occur independently of their host genes. 
 
circRNAs in exosomes 
Several recent reports have identified extracellular circRNAs(Y. Li et al. 2015). To test 
whether circRNAs could be detected in the exosomes of colon cancer cell lines, we performed 
RNA-Seq analysis for exosomal RNAs from the three cell lines, each with three biological 
replicates. High quality circRNA candidates were identified in all three cell lines. However, the 
number of high quality candidates varied among the replicates. Because the variation between 
DKs-8 exosomal replicates was relatively low, we focused our downstream analyses on data 
from DKs-8 derived exosomes. High quality exosomal circRNA candidates identified in this cell 
line were well supported by paired end information. Specifically, the median percentages of 
properly paired back-splice mates were 90.0%, 91.3%, and 91.7% for the three replicates, 
respectively (Fig. 13A). Table 8 shows the ten most abundant exosomal circRNA candidates in 
distinct genes in DKs-8 cells. Interestingly, seven of these circRNAs were also the top ten most 
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abundant circRNAs candidates in DKs-8 cells (Table 7).  
 
Table 8. Top10 most abundant circRNAs in exosomes 
Candidates Gene   DKs-8.1 DKs-8.2 DKs-8.3 
BSR
1 
PCMM
2 
BSR
1 
PCMM BSR
1 
PCMM2
 
chr5:95091100-95099324 RHOBTB3 81 95.1% 141 92.2% 89 95.5% 
chr11:33307959-33309057 HIPK3 75 81.3% 97 88.7% 51 90.2% 
chr4:187627717-187630999 FAT1 69 88.4% 78 94.9% 60 90.0% 
chr4:144464662-144465125 SMARCA5 44 97.7% 95 95.8% 61 88.5% 
chr1:117944808-117963271 MAN1A2 36 83.3% 65 95.4% 37 94.6% 
chr20:30954187-30956926 ASXL1 28 85.7% 60 85.0% 33 90.9% 
chr12:120592774-120593523 MIR4498 40 92.5% 44 97.7% 28 89.3% 
chr2:55209651-55214834 RTN4 28 85.7% 43 88.4% 35 100.0% 
chr9:138773479-138774924 CAMSAP1 21 95.2% 36 91.7% 34 82.4% 
chrM:2003-2226 MT-RNR2 67 92.5% 18 90.9% 3 100.0% 
 Abbreviations: BSR1= Back-spliced reads; PCMM2= Percentage of back-splice mates with Corresponding Mates 
  
 
 
  
 
 
 
To validate the RNA-Seq results, qRT-PCR analysis was also performed on these 
consistently present and abundant circRNA candidates in exosomes. As shown in Fig. 13B, five 
of these circRNAs were confirmed as present in exosomes and three of them were differentially 
Figure 13: Bioinformatics analysis of circRNAs in exosomes. (A) Distribution of PCMM values for three DKs-8 
exosomes replicates. (B) RT-PCR results for five selected circRNAs between mutant and wild-type cell lines in 
exosomes. (C) RT-PCR results for host genes of confirmed circRNAs in exosome. (Two-tailed, paired t-test was 
used for the analysis. *Denote p values ≤ 0.1 and **≤0.05). 
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expressed in at least one set of mutant cell line derived exosomes compared with the wild-type 
cell line exosomes (two-tailed, paired t-tests was used for the analysis, where *are p values ≤ 0.1 
and **≤0.05). Among them, circFAT1 was significantly down regulated in DKO-1 as compared 
to DKs-8 exosomes (Fig. 13B); this circRNA followed the same trend in cells (Fig. 12E). 
Meanwhile, circRTN4 was significantly up regulated in DLD-1 exosomes (Fig. 13B), while it 
was significantly down regulated in DLD-1 cells (Fig. 12E). The mRNA expression levels of 
these circRNA host genes were also tested by qRT-PCR and the results shown in Fig. 13C. The 
mRNA expression levels of both FAT1 and RTN4 were up regulated in exosomes from mutant 
KRAS cells. Therefore the shift in the relative circRNA levels was not the same as that for their 
linear mRNA host genes when comparing mutant and wild-type KRAS-derived exosomes. These 
results suggested that there is a complex exosomal trafficking mechanism for circular RNAs. 
This is interesting given the increased abundance of RNA-binding proteins present in wild-type 
KRAS as compared to mutant KRAS cell-derived exosomes(Demory Beckler et al. 2012). Results 
from the proteomic analysis of these exosomes may explain both the relative differences in 
circRNA and linear RNA content in DKs-8 as compared to DKO-1 and DLD-1 exosomes, as 
well as the relatively consistent levels of such RNAs in DKs-8 exosomes, given that such RNAs 
might be trafficked by these specifically exosomally-localized DKs-8 enriched RNA-binding 
proteins. 
 
Relative abundance of circular and linear transcripts 
Because RNAse R treatment was not applied during the RNA library construction in this 
study, the resulting RNA-Seq data allowed us to directly compare the abundance of circRNAs 
and their linear host RNAs. Similar to previous studies(Salzman et al. 2013; Rybak-Wolf et al. 
2015), we used the ratio between Expression level of exons With Circular RNAs and Expression 
level of exons with No Circular RNAs (EWC/ENC) to quantify the relative abundance of these 
two types of transcripts. 
For cellular RNAs, the median EWC/ENC ratios ranged from 1.57 to 1.84 across the 
three cell lines (Fig. 14A). Similar analysis was performed on exosomal RNAs, where the 
median EWC/ENC ratios were much higher and ranged from 2.56 to 4.26 (Fig. 14B). Figure 
14C and D show the read coverage depth plots for the most abundant circRNA circFAT1 
(chr4:187627717-187630999) in DKs-8 cells and exosomes, respectively. The exon 
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corresponding to circFAT1 (red) had a much higher read depth compared with other exons 
(blue). The EWC/ENC ratios were 3.5 and 3.0 for the two cell replicates, respectively, and 7.1, 
7.6, and 7.7 for the three exosome replicates, respectively. These results are consistent with 
recent reports that circRNAs are more abundant than their host linear RNAs(Salzman et al. 2013; 
Rybak-Wolf et al. 2015) and provide additional evidence that circRNAs are likely to be more 
stable than their linear transcripts(Jeck and Sharpless 2014). In addition, our results suggest that 
cirRNAs are enriched in exosomes, which is consistent with a recent publication(Dou et al. 
2016). 
 
 
 
  
Figure 14: Relative expression levels of circRNAs compared to linear transcripts. (A,B) Distribution of 
EWC/ENC values for cellular and exosomal RNAs, respectively. DKO-1.exo.1 was excluded because only 2 
high quality candidates were identified in this replicate. (C,D) Expression levels of exons with and without 
circRNA with the FAT1 gene in DKs-8 cells and exosomes, respectively. 
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3.4. Discussion 
 
In this work, we determined the circRNA expression profiles in both cells and exosomes 
from three CRC cell lines that differ only in KRAS mutation status. Hundreds of high quality 
circRNA candidates were identified in cellular RNAs and we discovered that they could be 
transferred to exosomes. circRNAs tended to be more abundant in exosomes. Importantly, we 
showed that circRNA abundance was down-regulated at a global level in mutant KRAS cell lines, 
suggesting a potential involvement of circRNAs in oncogenesis. 
There are complex regulatory mechanisms for both circRNA and host gene expression. 
Although circRNAs were down-regulated in both DLD-1 and HCT166 based cell lines, it is 
difficult to conclude that the circRNAs are directly regulated by KRAS. One possibility is that 
down-regulation of circRNAs in KRAS mutant cells is caused by their increased exporting to 
exosomes. However, as shown in Fig. 14B, the EWC/ENC median values were 2.77, 4.15, 3.38, 
2.96 and 2.56 for KRAS mutant exosomes and were 4.26, 3.43 and 3.25 for KRAS WT exosomes 
(Fig. 12B). The median values in KRAS mutant exosomes were comparable to that in KRAS WT 
exosomes. Moreover, Fig. 13B shows that two of three significantly regulated circRNAs 
between KRAS mutant and WT exosomes were down-regulated in KRAS mutant (circFAT1 and 
circARHGAP5). These data suggest that circRNAs are not enriched in exosomes of the KRAS 
mutant cells. We also examined the expression levels of the RNA-editing enzymes ADAR and 
the RNA-binding protein QKI, which were reported as circRNA regulators(A. Ivanov et al. 
2015; Conn et al. 2015). The ADAR was decreased in the KRAS mutant cells, which may lead to 
an increase of circRNAs. QKI was down-regulated in KRAS mutant cells, which may lead to 
down-regulation of circRNAs. More broadly, we studied the expression levels of all RNA-
binding proteins from RBPDB(Cook et al. 2011), following the approach taken by Conn et 
al.(Conn et al. 2015). Six were found to be differentially expressed (FDR < 0.01 and absolute 
log2FC > 1) in KRAS mutant cell lines compared with wild-type cell lines (ELAVL2, RBMS3, 
BICC1, MSI1, RBM44, and LARP6). Three of these were up regulated and the others were down 
regulated. The most up-regulated gene, ELAVL2, can function as an alternative pre-mRNA 
splicing regulator in mammalian neurons(Ince-Dunn et al. 2012; J. M. Izquierdo 2008). The most 
down-regulated gene, MSI1, is also an important post-transcriptional regulator(Katz et al. 2014; 
Ratti et al. 2008). These genes may serve as candidate circRNA regulators. However, our 
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previous work shows that the correlation of mRNA and protein expression level is low for RNA-
binding proteins(B. Zhang et al. 2014). Further investigation will be needed to precisely define 
how circRNAs are regulated. 
 
 
3.5. Methods 
 
Cell Culture 
Cells were cultured in DMEM supplemented with 10% bovine growth serum until 80% 
confluent. To collect exosomes, cells were then washed 3 times with PBS and cultured for 24 hr 
in serum-free medium. The medium was collected and replaced with ionomycin-containing 
media for 1 hr, after which ionomycin-containing media was collected and pooled with the 
previously collected serum-free medium. 
 
Exosome isolation 
Exosomes were isolated from conditioned medium of DKO-1, Dks-8, and DLD-1 cells, with 
slight modification(Demory Beckler et al. 2012). Pooled media as describted above was 
centrifuged for 10 min at 300 × g to remove cellular debris, and the resulting supernatant was 
then filtered through a 0.22-um polyethersulfone filter (Nalgene, Rochester, NY) to reduce 
microparticle contamination. The filtrate was concentrated ~300-fold with a 100,000 molecular-
weight cutoff centrifugal concentrator (Millipore). The concentrate was then subjected to high-
speed centrifugation at 150,000 × g for 2 hr. The resulting exosome-enriched pellet was 
resuspended in PBS containing 25 mM HEPES (pH 7.2) and washed by centrifuging again at 
150,000 × g for 3 hr. The wash steps were repeated a minimum of 3 times until no trace of 
phenol-red was detected. The resulting pellet was resuspended in PBS containing 25 mM HEPES 
(pH 7.2) and protein concentrations were determined with a MicroBCA kit (Pierce). The number 
of exosomes per ug of protein was determined by nanoparticle tracking analysis (NanoSight, 
Wiltshire, UK).. Analysis was performed on three independent preparations of exosomes. 
 
RNA purification 
Total RNA from exosomes and cells was isolated using TRIzol (Life Technologies). In the case 
of exosomal RNA isolation TRIzol was incubated with 100 ul or less of concentrated exosomes 
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for an extended 15 min incubation prior to chloroform extraction. RNA pellets were resuspended 
in 60 μl of RNase-free water and were then re-purified using the miRNeasy kit (QIAGEN). Final 
RNAs were eluted with two rounds of 30 ul water extraction. 
 
mRNA library preparation and sequencing 
Total RNA containing both long RNA as well as miRNA fractions was extracted from exosomes 
or cell lines using Trizol followed by miRNeasy Kit purification. Final elution was in 60 μl 
RNase free sterile distilled water. The concentration and integrity of the extracted total RNA was 
estimated by Qubit
®
 2.0 Fluorometer (Invitrogen, Carlsbad, California), and Agilent 2100 
Bioanalyzer (Applied Biosystems, Carlsbad, CA), respectively. RNA samples with a RIN value 
of at least 7.0 or higher were used for further processing. 
Approximately 500 ng of total RNA was required for proceeding to downstream RNA-
seq applications. Briefly, a Ribo-zero Magnetic Gold rRNA removal kit (Epicenter, IIlumina 
Inc.) was used to remove ribosomal RNA from the total RNA. Next, first strand synthesis was 
performed using NEBNext RNA first strand synthesis module (New England BioLabs Inc., 
Ipswich, MA, USA). Immediately, directional second strand synthesis was performed using 
NEBNExt Ultra Directional second strand synthesis kit. Following this, cDNAs were used for 
standard library preparation protocol using NEBNext
®
 DNA Library Prep Master Mix Set for 
Illumina
®
 with slight modifications. Briefly, end-repair was performed followed by polyA 
addition and custom adapter ligation. Post-ligated materials were individually barcoded with 
unique in-house genomics service lab (GSL) primers. Library quality was assessed by Qubit 2.0 
Fluorometer, and the library concentration was estimated by utilizing a DNA 1000 chip on an 
Agilent 2100 Bioanalyzer. Accurate quantification for sequencing applications was determined 
using the qPCR-based KAPA Biosystems Library Quantification kit (Kapa Biosystems, Inc., 
Woburn, MA). Each library was diluted to a final concentration of 12.5 nM and pooled 
equimolar prior to clustering. Paired-End (PE) sequencing was performed on all samples. Raw 
reads were de-multiplexed using a bcl2fastq conversion software v1.8.3 (Illumina, Inc.) with 
default settings. 
 
circRNA identification 
Reads with length 100 bp were mapped to the UCSC hg19 human genome (with mitochondrial 
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sequences) by Bowtie 2 with up to 2 mismatches (version 2.2.3). Paired 3′ and 5′ end anchors 
with length 20 bp were extracted for each unmapped read. Anchor pairs were mapped to the 
above genome with no mismatches and up to 40 mapping positions using Bowtie 2. Refseq gene 
annotations from UCSC were used to annotate circRNA candidates. Custom PERL scripts were 
used to implement the pipeline. 
 
Contamination analysis 
We built a database with all bacterial and viral sequences from the NCBI nt 
database(ftp://ftp.ncbi.nlm.nih.gov/genomes/refseq/bacteria/assembly_summary.txt and 
ftp://ftp.ncbi.nih.gov/genomes/Viruses/). All back-splicing mates were blasted (ncbi-blast-
2.3.0+) against the database with default parameters. Next, back-splicing mates were linearly 
mapped to the bovine genome by Tophat2 (version 2.0.12) with up to 2 mismatches. Moreover, 
these mates were mapped to the bovine genome using the back-splicing detection algorithm 
described above. 
 
Differential expression analysis 
To count reads mapped normally to genes, paired end reads were mapped to the hg19 human 
genome using Tophat2 with up to 2 mismatches. Htseq-count (version 0.6.0) with default 
parameters was used to count reads mapped to genes with the refSeq annotation. It is worth 
noting that host gene expression was quantified using reads from both linear and circRNAs 
because existing tools cannot separate linear and circRNA counts based on RNA-Seq data from 
total RNAs. Accordingly, our results may have underestimated the difference between linear and 
circRNAs levels. The correlation between the regulation of linear and circRNAs would be even 
lower if we were able to separate the read counts. The EdgeR R package (version 3.6.8) was used 
for differential expression analysis. This package uses the Trimmed Mean of M-values (TMM) 
normalization method to remove systematic technical effects that occur in the data to minimize 
the impact of technical bias on differential expression analysis results. Moreover, the empirical 
Bayes method used in the package enables gene-specific variation estimates even when the 
number of replicate samples is very small. This method has been demonstrated in experiments 
with only two replicates, and thus is particularly appropriate for our study. For differential 
expression analysis of circRNAs, back-splicing read counts of circRNAs were added to the 
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bottom of gene count list as new genes for the normalization purpose. The cutoffs for log2 fold 
change (log2FC) and FDR were |log2FC| > 1 and FDR < 0.01. 
 
Evaluate circRNA candidates by paired end information 
To evaluate circRNA candidates by paired end sequencing information, corresponding mates of 
paired end reads were initially extracted for back-splice mapped mates. Then, fragments from the 
5′ ends of linear transcripts of circRNAs with length 100 nt were copied to the 3′ end of these 
linear transcripts. These mates were then mapped to the modified linear sequences using Tophat2 
with up to 2 mismatches. PCMM values were calculated as the number of reads both mates are 
mappable/the number of reads with back-splice mapped mate. 
 
Compare expression levels between circRNAs and linear transcripts 
To compare the relative expression levels between exons with and without circRNA candidates, 
DEPTH tool from Samtools package (version 0.1.19–44428 cd) was used to report read depths 
for genes with circRNA candidates. The mean value of read depths from an exon was used as the 
read depth of the exon. EWC/ENC value was calculated as the mean depth of exons with 
circRNAs/without circRNAs. 
 
RT-PCR 
To validate circRNA species, 0.5 ug of total RNA was reverse transcribed in a 30 μl reaction 
using AccuScript Hi-Fi RT kit with random hexamers according to manufactures protocol 
(#200820, Agilent Technologies). The resultant cDNA was diluted 4-fold in RNase- and DNase-
free water and approximately 14 ng was used as template for each qPCR reaction. qPCR was 
performed in technical triplicates for each amplicon using SsoAdvanced Universal SYBR
®
Green 
Supermix (Bio-Rad). qPCR reactions were conducted on a Bio-Rad CFX384 instrument and 
relative expression levels were obtained using cycle threshold (Ct) values obtained by instrument 
software. All Ct values ≥31 were considered as background and discarded from further analysis. 
Triplicate C(t) values were averaged and normalized to U6 snRNA. Fold-changes were 
calculated using the ΔΔC(t) method, where: Δ = C(t)circRNA - C(t)U6 snRNA, and 
ΔΔC(t) = ΔC(t)DKO or DLD − ΔC(t)DKs, and FC = 2^ΔΔC(t). Analysis was performed on three 
independent cell and exosomal samples. Forward (F) and reverse (R) primers used in qPCR 
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analysis were designed against head-to-tail junctions of putative circRNA products as follows: 
FAT1- (F) ACGCCAGAGCCATCTCTAAT, (R) GCAATGGGGAGACATTTGGC; HIPK3- 
(F) ATGGCCTCACAAGTCTTGGT, (R) TGGCCGACCCAAAGTCTATT; ARHGAP5- (F) 
TGATCTTGAAGATGTTTCTGCACAG, (R) CATCTAACTCCTGGTCAGAAGTG; 
MAN1A2- (F) TTCGAGCTGATCATGAGAAGG, (R) GCAAGTAGGCCTCCAATAAA; 
RHOBTB3- (F) TAAAGGCTGAAGCGTCACATTAT, (R) 
CTCGATTACATTTGAAACATCCCCA; RTN4- (F) CAACTAAGAAGAGGCGCCTG, (R) 
AGACTGGAGTGGTGTTTGGT; SMARCA5- (F) GGCTTGTGGATCAGAATCTGAACA, 
(R) TCTCTATAGTCTTCTCCTTCGAAGT. All primer sequences are 5′ to 3. The primer 
sequences were blasted against the NCBI human genomic + transcript database to ensure specific 
amplification of the intended targets. Moreover, the melt curves showed that each primer set only 
had one specific peak, suggesting that the amplicon was specific and no other secondary targets 
were being amplified. 
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Chapter 4 
 
 
Diverse long-RNAs are differentially expressed in exosomes secreted by mutant KRAS 
colorectal cancer cells 
 
 
4.1. Abstract 
There is growing evidence for the regulatory roles of extracellular RNAs in mediating cell-to-
cell communication. Although much is known about extracellular microRNAs (miRNAs), the 
identity and functional roles of non-miRNA biotypes are largely unknown. We have previously 
shown that mutant KRAS colorectal cancer (CRC) cells release exosomes containing distinct 
proteomes, miRNAs, and circular RNAs. To test whether mutant KRAS might regulate the 
composition of other RNA species, particularly long RNAs (mRNAs and lncRNAs), we 
comprehensively profiled RNAs of cells and matched exosomes from isogenic CRC cell lines 
differing only in KRAS status. We show that distinct RNAs, such as pseudogene and antisense 
transcripts, are enriched in exosomes compared to cellular profiles. Additionally, specific 
transcripts are differentially expressed dependent on mutant KRAS. For example, we observe 
strong enrichment of Rab13, as well as other novel ncRNAs in mutant KRAS exosomes.  In co-
culture experiments, we have implemented a novel RNA-tracking system to monitor the delivery 
of extracellular RNAs to recipient cells. Uptake of a guide-RNA fusion from donor cells 
activates reporter expression in recipient cells. Here, we present comprehensive data to identify 
the broad and diverse classes of extracellular RNAs secreted in exosomes and we demonstrate 
that export of specific RNAs can be regulated by KRAS status. Collectively, this will advance our 
understanding of exRNA biology in CRC and facilitate the development of potential exRNA 
biomarkers. 
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4.2. Introduction 
It is now known that the majority of genome is transcribed into RNA but only ~2-3% of 
the genome encodes proteins.  The remaining non-coding RNAs (ncRNAs) play important 
regulatory roles in mediating gene expression in eukaryotes and prokaryotes, and in nearly every 
biological context (Reinhart et al. 2000, 7). Recently, numerous studies have demonstrated the 
presence of distinct types of extracellular RNA (exRNAs) in diverse biological fluids (Valadi et 
al. 2007; Andrey Turchinovich et al. 2011). With respect to exRNAs, studies have focused 
primarily on microRNAs (miRNAs) which are well annotated with known regulatory functions 
(Kozomara and Griffiths-Jones 2011; Alvarez-Garcia and Miska 2005). However, the diversity 
of exRNAs is extensive and miRNAs are often not the most abundant class of RNA found in 
EVs (Balkom et al. 2015). The biological functions of these non-miRNA species are largely 
unknown. 
Circulating RNAs are protected within ribonucleoprotein complexes (RNPs) (Arroyo et 
al. 2011), complexed with lipids (Vickers et al. 2011; Tabet et al. 2014), or incorporated into 
extracellular vesicles (EVs) (Valadi et al. 2007).  EVs are an umbrella term referring to 
membrane-delimited nanovesicles released by all cells (Maas, Breakefield, and Weaver 2016), 
including exosomes, microvesicles, and other secreted vesicles (for review, see (Graça Raposo 
and Stoorvogel 2013)). Each class of vesicle is unique in its origin, and thus, differs in its 
composition of lipid, protein and RNA cargo (Colombo, Raposo, and Théry 2014; Patton et al. 
2015). Here, we will focus on exosomes, small vesicles (40-100nm) that arise through the 
endosomal pathway (Graça Raposo and Stoorvogel 2013). 
It has been suggested that protein cargo transfer by EVs between cells is associated with 
tumor aggressiveness and metastasis(Skog et al. 2008; Higginbotham et al. 2011b; Hoshino et al. 
2013). However, numerous reports have also demonstrated that specific RNA species are sorted 
into exosomes and EVs and can function in cell-to-cell communication (Squadrito et al. 2014; 
Villarroya-Beltri et al. 2013b; Bellingham, Coleman, and Hill 2012). Dysregulation of various 
RNAs, such as miRNAs and lncRNAs, have been associated with disease, including cancer. 
Secretion of any of these various RNAs could contribute to modulation of the tumor 
microenvironment and metastasis through extracellular signaling. Therefore, identifying the full 
complement of circulating RNAs in normal and disease states could serve as useful biomarkers 
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in the diagnosis and prognosis of different types of malignancies, as well as for potentially 
monitoring the response to treatments (Creemers, Tijsen, and Pinto 2012; Berrondo et al. 2016). 
Elucidation of the potential mechanisms for selective sorting of cargo into exosomes is critical to 
understanding extracellular signaling by RNA.   
KRAS mutations occur in approximately 34-45% of colon cancers(Wong and 
Cunningham 2008). In our ongoing efforts to understand the biological and pathological role of 
exRNAs regulated by oncogenic signaling, we utilized three isogenic colorectal cancer cell lines 
that differ only in the mutational status of the KRAS gene. The parental DLD-1 cell line contains 
both wild-type and G13D mutant KRAS alleles, while the isogenically-matched derivative cell 
lines contain either one mutant KRAS allele (DKO-1) or one WT KRAS allele (DKs-8)(Senji 
Shirasawa et al. 1993). We have previously shown that exosomes from mutant KRAS CRC cells 
can be transferred to wild type cells to induce cell growth and migration(Higginbotham et al. 
2011b; Demory Beckler et al. 2012). Additionally, we found that the miRNA profiles of 
exosomes from all three cell lines are distinct from the parental cell, and segregate depending on 
the mutation status of KRAS (Cha et al. 2015). More recently, we identified a global 
downregulation of circular RNAs (circRNAs) in mutant KRAS cells with an inverse upregulation 
in exosomes (Dou et al. 2016).   
In this study, we extended our RNA-seq analysis on DLD-1 CRC cells and isogenic 
derivatives, as well as their secreted exosomes.  We conducted comprehensive analysis of long 
RNAs to determine whether long coding and noncoding transcripts are selectively sorted to 
exosomes. 
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4.3. Results 
Distinct RNA classes are differentially distributed in exosomes 
Because exosomes derived from mutant KRAS cell lines have distinct proteomes 
(Demory Beckler et al. 2012), and miRNA profiles (Cha et al. 2015) compared to both exosomes 
from WT cells and from parental cellular profiles, we hypothesized that KRAS signaling could 
alter sorting of long RNA species in exosomes.  We performed directional RNA-seq on 
ribosomal RNA-depleted total RNA libraries from isogenically matched CRC cell lines that 
differ only in KRAS status (Table 3) and their cognate exosomes. Exosomes were isolated 
through a series of differential centrifugations, as previously described (Higginbotham et al. 
2011b), and consisted of EVs approximately 40-130 nm in diameter (Demory Beckler et al. 
2012). Sequence alignment to the human genome revealed that the mapping percentages were 
much higher in cellular datasets compared to exosomes. For all cellular profiles, 76-78% of 
paired reads were mapped to the genome, while in exosomes, mapping percentages were much 
lower (DKs-8=35-56%, DKO-1=49-54%, DLD-1=37-49%)(Table 9). The decreased abundance 
of mappable reads is not due to amplification and sequencing of contaminating RNAs but rather 
due to the fact that numerous mismatches were detected in exosomal RNA compared to parental 
RNA populations. It appears that many RNAs detected in exosomes are enriched in base 
modifications that could alter base reads during reverse transcription and PCR amplification.    
 
Table 9. Percent of reads mapping to the human genome 
Data Total 
Paired reads Left mate Right mate 
Mapped 
Unique 
mapped 
Mapped 
Unique 
mapped 
Mapped 
Unique 
mapped 
DKO-1.cell.1 111585679 77.6% 68.1% 83.1% 72.4% 85.2% 74.2% 
DKO-1.cell.2 120022437 77.3% 68.5% 82.8% 72.9% 84.8% 74.6% 
DKO-1.cell.3 120636161 77.3% 67.8% 82.6% 71.9% 84.8% 73.8% 
DLD-1.cell.1 122984756 77.7% 68.8% 83.1% 73.0% 85.1% 74.9% 
DLD-1.cell.2 131668189 76.6% 67.5% 82.6% 72.2% 84.2% 73.6% 
DLD-1.cell.3 118751417 77.6% 69.1% 83.3% 73.7% 85.0% 75.3% 
DKs-8.cell.1 120608612 77.2% 67.2% 82.7% 71.6% 84.8% 73.2% 
DKs-8.cell.2 126181872 77.8% 69.1% 83.3% 73.5% 85.3% 75.3% 
DKs-8.cell.3 131998156 78.4% 70.2% 84.3% 74.9% 85.8% 76.2% 
DKO-1.exo.1 114041294 53.9% 47.0% 64.2% 55.6% 62.3% 53.9% 
DKO-1.exo.2 109044100 54.9% 47.1% 64.6% 55.0% 63.7% 54.1% 
DKO-1.exo.3 125124227 48.8% 45.1% 57.4% 53.0% 56.6% 52.1% 
DLD-1.exo.1 120736524 37.2% 30.4% 45.2% 36.6% 45.9% 36.7% 
DLD-1.exo.2 119110502 47.2% 40.8% 57.9% 49.3% 56.3% 47.9% 
DLD-1.exo.3 120405815 48.5% 40.3% 57.6% 47.1% 57.2% 46.3% 
DKs-8.exo.1 120350227 35.1% 26.5% 41.3% 29.7% 41.7% 30.0% 
DKs-8.exo.2 113418948 54.0% 46.7% 63.8% 54.6% 62.8% 53.6% 
DKs-8.exo.3 115990041 56.1% 49.9% 67.4% 59.6% 64.8% 57.3% 
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 After mapping to known gene regions and performing pairwise analyses between 
samples, cell replicates showed very high correlation (r=0. 91-0.94), while exosomal replicates 
were less correlated (r=0.76-0.95) (Figure 15). This is likely due to the inherent heterogeneity of 
purified EV preparations compounded by batch variance in sequencing runs. However, RNA 
profiles from exosomes compared to their parental cells showed the least correlation (DKO-1 
r=0.68-0.72, DKs-8 r=0.68-0.78, DLD-1 r=0.66-0.73) (Figure 15). In cellular datasets, a high 
percentage of reads corresponded to annotated gene regions (~57-62%), but only a small 
percentage was observed in exosomal profiles (5-16%) (Figure 16a). In addition to base 
modifications than might alter sequence reads, some transcripts likely represent novel RNA 
species that map to unannotated loci. 
To determine the different biotypes of RNA in cell and exosomes, we mapped reads 
against genotypes (Hg19, UCSC).  Although the majority of reads mapped to known protein 
coding sequences in both cellular and exosomal datasets, we identified reads from various 
classes of RNA, with differential enrichment between cell and exosomes (Figure 16b). For 
example, we observed enrichment for transcripts derived from pseudogenes and antisense RNAs 
in exosomes, which was almost undetectable in cell samples (≤0.3%)(Figure 16b). Because these 
pseudogenes contain miRNA binding sites in their 3’UTRs, they have the potential to regulate 
their corresponding coding gene expression by competing for miRNA binding (Poliseno et al. 
2010). The tumor suppressor gene PTEN and the oncogene KRAS both have pseudogenes, 
PTENP1 and KRAS1P, respectively (Poliseno et al. 2010). PTENP1 has been shown to regulate 
PTEN levels and exert a growth-suppressive role. Furthermore, down regulation of PTEN 
expression was associated with focal copy number losses at the PTENP1 locus in sporadic colon 
cancer patient samples (Poliseno et al. 2010). A similar relationship was observed between 
oncogene KRAS and its pseudogene KRAS1P, where transcript levels are positively correlated in 
different tumors(Poliseno et al. 2010), suggesting a proto-oncogenic role for KRAS1P.  In cell 
datasets, a higher percentage of transcripts corresponding to protein coding and lincRNAs were 
observed. These data suggest that distinct biotypes of RNAs are selectively sorted to exosomes 
or retained within the cell, independent of KRAS status.  
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Figure 15. Pairwise similarity between all samples. Spearman correlation analysis was performed on all 
cellular and exosomal samples. DKO-1, DLD-1 and DKs-8 cell samples showed high correlation (r=0.91-
0.92; 0.91; 0.92-0.93, respectively). Exosome samples were more varied (r=0.91-0.94 DKO-1, 0.82-0.93 
DLD-1, 0.76-0.95 DKs-8). 
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Figure 16. Long sequencing analysis of cellular and exosomal RNAs from CRC cell lines. Shown are 
total percentage of mapped reads to (A) gene regions, and (B) different gene types. The majority of reads 
map to protein coding sequences (dark blue) in both cellular and exosomal datasets.  In cells, many more 
reads map to lincRNAs (yellow), whereas in evosomes, transcripts mapping to pseudogenes (orange) and 
antisense (dark green)) are increased.  
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To determine whether the overall long RNA profiles are distinct between cells and 
exosomes and between wild-type and mutant KRAS status, we performed Principal Component 
Analysis (PCA). PCA analysis revealed that the repertoire of long RNAs is clearly distinct when 
comparing parental cell RNA profiles and their secreted exosomal RNAs (Figure 17a). When 
comparing cellular profiles across the three lines, the RNA expression patterns clustered 
together, suggesting that KRAS-driven differential RNA expression is more pronounced when 
comparing exosomes to cells as opposed to comparing between the three cell lines. It is worth 
noting that the exosomal profiles varied from batch to batch, suggesting that secreted RNAs may 
be much more sensitive to various factors and are dynamically regulated.   
Differential gene expression analyses were performed comparing cellular RNAs to their 
cognate exosomes, cellular RNAs between the three cell lines differing in KRAS status (mutant 
cell/WT cell), and exosomal RNA profiles differing in KRAS status (mutant exo/WT exo). 
When comparing exosomes to their parent cells, we found 16,000 RNAs enriched in DKO-1 
exosomes, while only 2,400 and 1,600 RNAs were enriched in DLD-1 and DKs-8 exosomes, 
respectively (Figure 17b). This suggests that the diversity of transcripts when comparing mutant 
DKO-1 exosomes to its cognate cell line is much more different than when comparing the 
exosomes and cells from either WT (DKs-8) or heterozygote (DLD-1) cells, similar to what we 
observed in our previous miRNA profiles (Cha et al. 2015). 
 
Differential enrichment of RNA transcripts in exosomes 
 We observed several transcripts to be overrepresented in exosomes compared to their 
parental cells. Several transcripts were much more abundant in mutant DKO-1 exosomes 
compared to WT DKs-8 exosomes, several of which have known roles in oncogenesis. Rab13 
was >21-fold up-regulated in DKO-1 exosomes, whereas in DKs-8 exosomes, enrichment for 
Rab13 was <4-fold. We observed reads spanning the entire coding sequence for Rab13 in both 
cellular and exosomal datasets. Because a caveat of long RNA sequencing is that it cannot 
precisely distinguish between full-length or fragmented sequences, we performed RT-PCR to 
determine transcript lengths. PCR analysis on Poly(A)-selected RNAs confirmed the presence of 
full-length Rab13 in both exosomes and cells. Interestingly, RAB13 protein was also enriched in 
mutant exosomes in our previous proteomic analysis (Demory Beckler et al. 2012). In our 
libraries 
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 In addition to protein coding sequences, we found enrichment of several lincRNAs in 
mutant KRAS exosomes. RP11-946L20.4, more recently annotated as LINC01609 in 
ENSEMBL, is a novel lincRNA ~456 nt in length with no characterized functions. 
 
 
Figure 17. Long RNAs are differentially enriched in cells and exosomes. A) Comparative Principal 
Component Analysis (PCA) reveals that cellular long RNA profiles are clustered together and are similar, 
independent of KRAS status (light colors). Exosome profiles are distinct from the parent cell, and are more 
variable between replicates. Venn diagram shows that several RNA transcripts are differentially represented in 
B) cells and D) exosomes. 
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Table 10. Top 50 Differentially Expressed RNA Transcripts In Exosomes 
Gene Gene symbol Detail of gene name DKO1  
E/C1 
DLD1 
E/C1 
DKs8 
E/C1 
ENSG00000205176.2 REXO1L1 REX1, RNA exonuclease 1 homolog (S. 
cerevisiae)-like 1 
159.17 73.06 123.48 
ENSG00000253103.1 RP11-
946L20.4 
NULL 86.91 39.18 39.13 
ENSG00000213121.2 AL590867.1 NULL 56.22 26.47 26.43 
ENSG00000213121.2 AL590867.1 NULL 56.22 26.47 26.43 
ENSG00000173198.4 CYSLTR1 cysteinyl leukotriene receptor 1 52.48 26.83 25.68 
ENSG00000248360.3 LINC00504 NULL 47.55 24.50 26.06 
ENSG00000173212.4 MAB21L3 mab-21-like 3 (C. elegans) 44.28 23.10 22.99 
ENSG00000249614.1 RP11-703G6.1 NULL 41.68 18.95 19.99 
ENSG00000259380.1 RP11-
346D14.1 
NULL 39.50 19.81 19.28 
ENSG00000225914.1 XXbac-
BPG154L12.4 
NULL 36.74 18.25 16.90 
ENSG00000069431.6 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 9 
30.12 14.88 15.31 
ENSG00000165805.5 C12orf50 chromosome 12 open reading frame 50 28.95 14.74 13.56 
ENSG00000143545.4 RAB13 RAB13, member RAS oncogene family 21.82 5.76 3.52 
ENSG00000236008.1 AC011747.4 NULL 21.28 12.18 14.46 
ENSG00000249348.1 UGDH-AS1 UGDH antisense RNA 1 20.70 10.24 10.96 
ENSG00000249731.1 RP11-259O2.3 NULL 18.48 9.25 10.56 
ENSG00000150477.10 KIAA1328 KIAA1328 17.22 9.84 10.25 
ENSG00000237515.6 SHISA9 shisa homolog 9 (Xenopus laevis) 16.00 8.02 7.02 
ENSG00000269821.1 KCNQ1OT1 KCNQ1 opposite strand/antisense transcript 1 (non-
protein coding) 
12.84 6.13 6.13 
ENSG00000233251.3 AC007743.1 NULL 12.80 6.88 5.59 
ENSG00000133138.15 TBC1D8B TBC1 domain family, member 8B (with GRAM 
domain) 
12.55 6.59 6.59 
ENSG00000181458.6 TMEM45A transmembrane protein 45A 12.39 6.00 5.53 
ENSG00000115993.7 TRAK2 trafficking protein, kinesin binding 2 10.11 2.43 1.14 
ENSG00000151338.14 MIPOL1 mirror-image polydactyly 1 9.63 5.33 2.02 
ENSG00000173848.14 NET1 neuroepithelial cell transforming 1 9.30 1.93 1.41 
ENSG00000129250.7 KIF1C kinesin family member 1C 9.17 2.41 1.72 
ENSG00000136938.8 ANP32B acidic (leucine-rich) nuclear phosphoprotein 32 
family, member B 
7.26 1.36 1.59 
ENSG00000153179.7 RASSF3 Ras association (RalGDS/AF-6) domain family 
member 3 
7.04 1.37 1.02 
ENSG00000143951.11 WDPCP WD repeat containing planar cell polarity effector 4.99 2.54 3.12 
ENSG00000198786.2 MT-ND5 NULL 4.82 0.40 0.45 
ENSG00000079482.11 OPHN1 oligophrenin 1 4.09 2.43 2.02 
ENSG00000139974.11 SLC38A6 solute carrier family 38, member 6 3.61 2.03 1.30 
ENSG00000069869.11 NEDD4 neural precursor cell expressed, developmentally 
down-regulated 4, E3 ubiquitin protein ligase 
3.13 2.01 3.31 
ENSG00000140450.7 ARRDC4 arrestin domain containing 4 3.04 0.96 0.49 
ENSG00000166377.15 ATP9B ATPase, class II, type 9B 2.57 1.59 1.76 
ENSG00000104164.6 BLOC1S6 biogenesis of lysosomal organelles complex-1, 
subunit 6, pallidin 
2.43 1.53 1.93 
ENSG00000137831.10 UACA uveal autoantigen with coiled-coil domains and 
ankyrin repeats 
2.34 0.97 0.64 
ENSG00000198585.7 NUDT16 nudix (nucleoside diphosphate linked moiety X)-
type motif 16 
2.05 0.67 0.29 
ENSG00000143850.8 PLEKHA6 pleckstrin homology domain containing, family A 
member 6 
1.89 0.51 0.35 
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ENSG00000198899.2 MT-ATP6 NULL 1.87 0.24 0.26 
ENSG00000130517.9 PGPEP1 pyroglutamyl-peptidase I 1.76 0.36 0.21 
ENSG00000020577.9 SAMD4A sterile alpha motif domain containing 4A 1.66 0.59 0.62 
ENSG00000147224.6 PRPS1 phosphoribosyl pyrophosphate synthetase 1 1.65 0.44 0.22 
ENSG00000185963.9 BICD2 bicaudal D homolog 2 (Drosophila) 1.60 2.05 0.86 
ENSG00000170759.10 KIF5B kinesin family member 5B 1.49 0.23 0.30 
ENSG00000122484.8 RPAP2 RNA polymerase II associated protein 2 1.31 0.68 0.83 
ENSG00000236824.1 BCYRN1 brain cytoplasmic RNA 1 1.28 0.90 2.89 
ENSG00000112096.12 SOD2 superoxide dismutase 2, mitochondrial 1.27 0.80 0.93 
ENSG00000245532.4 NEAT1 nuclear paraspeckle assembly transcript 1 (non-
protein coding) 
0.24 0.03 0.10 
ENSG00000251562.3 MALAT1 metastasis associated lung adenocarcinoma 
transcript 1 (non-protein coding) 
0.08 0.02 0.09 
Abbreviations: E/C
1
=reads in exosomes / reads in cell; represents fold-change in exosomes compared to cells 
 
Extracellular transfer of RNA 
Unlike miRNAs which have clear functional roles in recipient cells, functional transfer of 
non-coding RNAs is much more difficult to assay. To test transfer of lncRNAs, we utilized a 
modified version of the CRISPR-Display system (Shechner et al. 2015). This system uses a short 
guide RNA (sgRNA) with an engineered loop that allows insertion of any RNA sequence of 
interest, either coding or non-coding. The sgRNA is used to target a dead Cas9 (dCas9) protein 
that is fused to VP64, a transcriptional activator to reporter constructs encoding luciferase 
(Shechner et al. 2015). To determine whether secreted long RNAs function in recipient cells, we 
designed a sgRNA containing miR-100 since we know that miR-100 is enriched in exosomes. 
This construct served as a positive control and showed 2-fold increase in luciferase expression 
compared to the unmodified sgRNA (Figure 18). Baseline activation of luciferase was measured 
in recipient DKs-8 cells co-cultured with donor cells expressing the empty control sgRNA 
(sgRNA-CTL). To test a lncRNA, we inserted the colorectal neoplasia differentially expressed 
(CRNDE) lncRNA within the sgRNA loop region (sgRNA-CRNDE). CRNDE transcripts were 
up-regulated in exosomes from our RNA-seq analysis (data not shown). This construct was 
therefore expressed in donor cells and co-cultured with DKs-8 recipient cells expressing dCas9-
VP64 and the luciferase reporter (Figure 19). In co-culture experiments where donor cells 
express the sgRNA-CRNDE construct, we observed a modest increase in luciferase activation 
(Figure 18). 
 
82 
 
 
 
 
 
  
Figure 18. CRISPR-display to track RNA transfer. A) Mutant DKO-1 or wild-type DKs-8 donor cells 
transiently expressing a short guide RNA (sgRNA) with an engineered loop (sgGLUC-CTL) containing 
CRNDE (sgGLUC-CRNDE), a non-coding RNA, or miR-100 (sgGLUC-miR100), a miRNA known to 
traffic to mutant exosomes. Recipient cells transiently expressing dCas9 fused to VP64, a CLUC normalizer, 
and a GLUC reporter that is activated only in the presence of the sgRNA. B) 24-hr co-culture reveals 
sgRNA-mediated GLUC activation in recipient DKs-8 cells in the presence of mutant DKO-1 donor cells 
expressing sgGLUC-miR100 and sgGLUC-CRNDE, but not sgGLUC-CTL. 
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4.4. Discussion 
From our analyses, we find that the RNA profiles are dramatically different in exosomes 
compared to the parent cells. We also find that certain transcripts are significantly enriched in 
mutant exosomes compared to WT-exosomes, suggesting that some RNAs are differentially 
regulated by KRAS-status. For example, Rab13 is up-regulated in mutant DKO-1 exosomes. 
Interestingly, Rab13  mRNA has been specifically detected in protrusions of metastatic breast 
cancer cells (Jakobsen et al. 2013). Unlike miRNA loading, which is presumably thought to 
occur at late endosomes (Gibbings et al. 2009), one possibility is that mRNA sorting occurs at 
the site of exosome release, thus favoring transcripts that localize to the periphery of the cell. 
Interestingly, analysis of fragmented and full-length mRNAs secreted by glioblastoma cells 
revealed that many of the full-length transcripts have functions in the extracellular matrix 
(Batagov and Kurochkin 2013). This supports the idea that mRNA loading and unloading into 
EVs occurs at sites that are functionally relevant. 
Despite numerous reports demonstrating the presence of mRNA in biofluids, it remains 
controversial whether these mRNAs are full-length or fragmented transcripts(Noerholm et al. 
2012). A caveat of long RNA sequencing is that it cannot distinguish between full-length or 
fragmented transcripts. Although an mRNA is assumed to be full-length when individual 
sequencing reads are mapped along the entire coding sequence, validation by RT-PCR is 
required to confirm the length of the transcript. In our libraries, we observed reads spanning the 
entire coding sequence for some mRNAs, such as Rab13, in both cellular and exosomal datasets, 
suggesting that these sequences are full-length. According to Ensembl, Rab13 has five known 
splice variants, three of which do not code for protein. Whether certain isoforms are specifically 
sorted to exosomes and whether these non-coding variants that arise from coding sequences have 
regulatory roles remains to be determined. 
 Currently, it unknown what the approximate size limitation is for inclusion into EVs. 
Given that the majority of EV-associated RNAs fall within a size distribution of 25-700 nt from a 
variety of biofluids (Pegtel et al. 2010; Noerholm et al. 2012), it is likely that most of the RNA 
transcripts present in EVs consist of short transcripts. These could represent full-length mRNAs 
that are <700 nt, or alternately, truncation of longer mRNAs. In addition to size limitations, it is 
unknown whether secreted long RNAs are characterized by a specific fragmentation or cleavage 
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pattern. In certain contexts, EV-associated mRNAs are largely enriched for 3’-UTR fragments 
(Batagov and Kurochkin 2013). Although we did not observe enrichment of these sequences in 
our libraries, this may have important implications in regulating gene expression in target cells 
since the 3’-UTRs of mRNAs are rich in regulatory sequences. Although the precise mechanisms 
for how 3’UTRs are selected for secretion are unknown, one possibility is that mRNAs undergo 
post-transcriptional cleavage to produce 3’UTR fragments, as reported by Mercer et al. (Mercer 
et al. 2011). Another possibility is that exosome-associated mRNAs undergo degradation after 
secretion via extracellular RNases. This seems unlikely, however, as we and others observe 
sequencing reads spanning both full-length transcripts as well as smaller/fragmented transcripts, 
suggesting that these fragments are generated within the cell before sorting into exosomes. 
Sorting of RNAs can occur by several processes. In certain contexts, RNAs can be 
trafficked to exosomes by cis-regulatory signals, such as sequence-specific motifs (elaborate). 
Furthermore, certain RNAs may localize to distinct cellular compartments based on biological 
functions. Our data reveal several potential long RNA CRC biomarkers and potential novel 
genes that, collectively, will advance our understanding of EV biology in CRC and accelerate 
the development of EV-based diagnostics and therapeutics.” 
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4.5. Methods 
Exosome isolation 
Exosomes were isolated from conditioned medium of DKO-1, Dks-8, and DLD-1 cells, with 
slight modification44. Pooled media as describted above was centrifuged for 10 min at 
300 × g to remove cellular debris, and the resulting supernatant was then filtered through a 
0.22-um polyethersulfone filter (Nalgene, Rochester, NY) to reduce microparticle 
contamination. The filtrate was concentrated ~300-fold with a 100,000 molecular-weight 
cutoff centrifugal concentrator (Millipore). The concentrate was then subjected to high-speed 
centrifugation at 150,000 × g for 2 hr. The resulting exosome-enriched pellet was resuspended 
in PBS containing 25 mM HEPES (pH 7.2) and washed by centrifuging again at 150,000 × g 
for 3 hr. The wash steps were repeated a minimum of 3 times until no trace of phenol -red was 
detected. The resulting pellet was resuspended in PBS containing 25 mM HEPES (pH 7.2) and 
protein concentrations were determined with a MicroBCA kit (Pierce). The number of 
exosomes per ug of protein was determined by nanoparticle tracking analysis (NanoSight, 
Wiltshire, UK). Analysis was performed on three independent preparations of exosomes. 
RNA purification 
Total RNA from exosomes and cells was isolated using TRIzol (Life Technologies). In the 
case of exosomal RNA isolation TRIzol was incubated with 100 ul or less of concentrated 
exosomes for an extended 15 min incubation prior to chloroform extraction. RNA pellets were 
resuspended in 60 μl of RNase-free water and were then re-purified using the miRNeasy kit 
(QIAGEN). Final RNAs were eluted with two rounds of 30 ul water extraction. 
 
mRNA library preparation and sequencing 
Total RNA containing both long RNA as well as miRNA fractions was extracted from 
exosomes or cell lines using Trizol followed by miRNeasy Kit purification. Final elution was 
in 60 μl RNase free sterile distilled water. The concentration and integrity of the extracted 
total RNA was estimated by Qubit
®
 2.0 Fluorometer (Invitrogen, Carlsbad, California), and 
Agilent 2100 Bioanalyzer (Applied Biosystems, Carlsbad, CA), respectively. RNA samples 
with a RIN value of at least 7.0 or higher were used for further processing. 
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Approximately 500 ng of total RNA was required for proceeding to downstream RNA -seq 
applications. Briefly, a Ribo-zero Magnetic Gold rRNA removal kit (Epicenter, IIlumina Inc.) 
was used to remove ribosomal RNA from the total RNA. Next, first strand synthesis was 
performed using NEBNext RNA first strand synthesis module (New England BioLabs Inc., 
Ipswich, MA, USA). Immediately, directional second strand synthesis was performed using 
NEBNExt Ultra Directional second strand synthesis kit. Following this, cDNAs were used for 
standard library preparation protocol using NEBNext
®
 DNA Library Prep Master Mix Set for 
Illumina
®
 with slight modifications. Briefly, end-repair was performed followed by polyA 
addition and custom adapter ligation. Post-ligated materials were individually barcoded with 
unique in-house genomics service lab (GSL) primers. Library quality was assessed by Qubit 
2.0 Fluorometer, and the library concentration was estimated by utilizing a DNA 1000 chip on 
an Agilent 2100 Bioanalyzer. Accurate quantification for sequencing applications was 
determined using the qPCR-based KAPA Biosystems Library Quantification kit (Kapa 
Biosystems, Inc., Woburn, MA). Each library was diluted to a final concentration of 12.5 nM 
and pooled equimolar prior to clustering. Paired-End (PE) sequencing was performed on all 
samples. Raw reads were de-multiplexed using a bcl2fastq conversion software v1.8.3 
(Illumina, Inc.) with default settings. 
 
Read Mapping 
Reads sequencing quality check were performed using fastQC (v0.11.2). Results are shown in 
the folder: /dors/bioinfo/exrna/human/dld/rnaseq_batch3_gencode/02RawQC. Reads were 
mapped to the human genome hg19 (UCSC) using tophat2 (v2.0.13) with bowtie2 (version 
2.2.3). Parameters for the mapping are -p 12 -g 10 -r 50 --mate-std-dev 50 --library-type fr-
firststrand -G gencode.v19.annotation.gtf. The above gene annotation is form Gencode project 
version 19. Htseq-count (version 0.6.1p1) was used for counting with parameters: -f bam -s 
reverse -r name -a 10 and with the same annotation to mapping. DESeq (version 1.16.0), based 
on negative binomial distribution, was used to differential analysis and PCA analysis.. The 
trimmed mean of M values (TMM) method was used as normalization method in the analysis. 
The cutoffs for log2 fold change (log2FC) and PDR are |log2FC| >= 1 and FDR <= 0.001. 
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Chapter 5 
 
 
Discussion 
 
 
 There is growing evidence for the regulatory roles of EV-associated exRNAs in 
transferring genetically encoded messages to mediate cell-to-cell communication. They have 
been implicated in normal developmental processes, such as fetal-maternal exchange during 
pregnancy (Adam et al. 2017) and antigen presentation in immunity (Graca Raposo et al. 1996), 
as well as in the progression of several diseases, including neurodegeneration (Lehmann et al. 
2012), cardiovascular dysfunction (Bang et al. 2014), and cancer (D’Souza-Schorey and Clancy 
2012). EVs are present in various body fluids, and can potentially reflect the status of the source 
cell, making them attractive candidates as clinical biomarkers to monitor disease (Cortez et al. 
2011). Additionally, since EVs can transfer RNA and protein cargo, they are being explored as 
delivery vehicles for therapeutic purposes (Andaloussi et al. 2013). The field of EV and exRNA 
research is relatively new, and although much progress has been made in characterizing the 
various classes and composition of EVs, the precise mechanisms of their biogenesis and function 
in biological systems are still largely elusive. This section will address the significance and 
future directions of this work, as well as discuss the current challenges in the field. 
 
 
5.1. Significance  
 
 
Colon cancer is the third most commonly diagnosed cancer, and is the second leading 
cause of cancer-related deaths in the US (www.cancer.org). Activating mutations in KRAS occur 
in approximately 34-45% of colon cancers (Wong and Cunningham 2008), and can predict 
resistance to anti-EGFR monoclonal antibodies used to treat patients with metastatic CRC. Given 
the potential of cancer-derived secreted RNAs in driving formation of the pre-metastatic niche, 
identifying the mechanisms for cargo sorting into EVs is critical to understand extracellular 
signaling by RNA. In these studies, we comprehensively examined the composition of RNAs 
from exosomes and cells of isogenic CRC cell lines that differ only in KRAS status. We show 
that certain RNAs are selectively enriched (described below) in mutant KRAS-derived exosomes 
compared to the parent cell and to wild type exosomes. KRAS status-specific patterns of secreted 
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RNAs support the idea of using exRNAs as potential biomarkers in CRC, and suggest a new 
mode of action for oncogenic KRAS. These studies have not only expanded our understanding of 
KRAS mutations in CRC, but also provided insights to novel elements of exRNA regulated by 
oncogenic signaling that are important for cancer biology and are of general relevance to 
multiple fields. 
In our small RNA sequencing analyses, we identified transcripts from various classes of 
RNA, with enrichment of specific biotypes in cellular and exosomal profiles. Given that 
microRNAs (miRNAs) are perhaps the best characterized class of small noncoding RNAs that 
have been detected in extracellular fluids (Valadi et al. 2007), and they have the potential to 
regulate hundreds of transcripts within a genome(Bartel 2004), our initial studies focused on 
defining extracellular miRNAs. We found that specific miRNAs are preferentially secreted by 
mutant KRAS cells (miR-100), whereas other miRNAs, such as miR-320 family members, are 
secreted in exosomes, independent of KRAS status. Neutral sphingomyelinase inhibition caused 
accumulation of both miRNAs only in mutant KRAS cells, suggesting that lipid composition 
and/or RNA export may be differentially regulated by oncogenic signaling. Finally, secretion of 
miR-100 from mutant KRAS donor cells mediated target repression in wild type recipient cells. 
This supports the hypothesis that extracellular miRNAs can function beyond the cell of origin. 
In our long RNA sequence analyses, we found that circular RNAs (circRNAs) are 
globally downregulated in mutant KRAS cells, but in contrast, tended to be more abundant in 
exosomes, suggesting a potential involvement of circRNAs in oncogenesis. SMARCA5 was 
among the top ten circRNA candidates enriched in exosomes. Interestingly, linear SMARCA5 is 
targeted by miR-100 which subsequently promotes epithelial to mesenchymal transition (D. 
Chen et al. 2014). It remains to be determined whether miR-100 can also regulate levels of 
circular SMARCA5.  Although the precise function(s) of circRNAs remains largely unknown, it 
has been proposed that they can act as miRNA sponges (Hansen, Kjems, and Damgaard 
2013).Whether circRNA in exosomes might function as competing exogenous RNA in recipient 
cells will require further investigation. 
In addition to circRNAs, we identified enrichment of pseudogenes and antisense 
transcripts in exosomes compared to cellular profiles. The most upregulated transcript in 
exosomes was RNA exonuclease 1 homologue (S. cerevisiae)-like 1 gene (REXO1L1), a 
pseudogene cluster that lies within a 12 kb tandem repeat in 8q21.2, one of the largest variable 
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number tandem repeat arrays in the human genome (Warburton et al. 2008). REXO1L1 is a 
member of the 3’-5’ exonuclease DEDD superfamily that has been associated with inflammatory 
diseases (Hollox and Hoh 2014) and RNA virus infections (Barber et al. 2017). Although 
additional experiments are needed to elucidate the functional consequences of these transcripts, 
pseudogenes can be processed into siRNAs and function through the RNAi pathway, or can act 
as miRNA decoys, and thus, have the potential to regulate their cognate coding gene (Poliseno et 
al. 2010; Pink et al. 2011).  
 Overall, we present comprehensive data to identify the broad and diverse classes of 
exRNAs secreted in exosomes and we show that exports of specific RNAs are differentially 
regulated by oncogenic KRAS. Understanding the correlation of exRNAs with disease 
progression and therapy response will facilitate the use of liquid biopsies as a clinical tool for 
cancer diagnosis, precluding the need for direct tumor sampling. Furthermore, since exRNAs can 
potentially regulate a variety of cellular processes in the tumor microenvironment and the tumor 
proper, we can use this information to develop novel drug delivery vehicles and alternate 
therapies for CRC. 
 
 
5.2. Discussion and future directions 
 
 
Composition of RNA secreted in EVs 
Differential RNA expression is more prominently affected in secreted RNAs than in the 
parent cells.  This could reflect the dynamic regulation of RNAs that are often times kept at 
steady states, and thus, masked witihin the cell. This also suggests that cells may implement 
mechanisms to selectively export certain RNAs to maintain specific growth or gene expression 
states.  In the context of miRNAs, this is consistent with a recent report that found that the 
cellular levels of certain miRNAs could be maintained, despite changes in the abundance of its 
target, likely through a “miRNA relocation effect” where unbound miRNAs that are in excess 
have the potential to be sorted to exosomes(Squadrito et al. 2014) . As circRNAs are reported to 
bind miRNAs to function as a miRNA sponge (Hansen et al. 2013), it was demonstrated that 
exogenous expression of miR-7 in MCF-7 cells caused significant decrease in exosomal levels of 
CDR1as exosomes (Y. Li et al. 2015), a circRNA known to act as a miR-7 sponge (Hansen et al. 
2013). This suggests that sorting of circRNAs to EVs are regulated, at least in part, by changes in 
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expression level of its associated miRNA in the parent cell. 
In contrast to cellular profiles which displayed an enrichment of miRNA sequences 
(~70%), miRNA sequences make up just a small percentage in exosomes (<18%) compared to 
other class of ncRNA (repeat sequences, tRNAs, rRNAs). It was recently shown that lymphoma 
cell-derived exosomes are predominantly enriched with human yRNA fragments (Koppers-Lalic 
et al. 2014). Although the biological relevance of yRNAs in exosomes is unclear, yRNAs are 
known to be specifically packed in enveloped and non-eveloped viral particles (Garcia et al. 
2009). The selective enrichment of these RNAs from the host cell into viral particles and 
exosomes implies that common molecular mechanisms may be regulating their packaging.  
Given that the RNA profiles in exosomes do not simply reflect the cell or origin, it remains to be 
determined exactly how these small ncRNAs are trafficked to exosomes. 
Despite initial reports identifiying mRNAs in EVs (Valadi et al. 2007), it remains 
controversial whether these mRNAs are full-length or fragmented transcripts(Noerholm et al. 
2012). Intact mammalian mRNAs vary in length from 400 nucleotides (nt) up to >100,000 nt, 
with the average transcript being ~2,100  nt in size (Lander et al. 2001). However, the majority 
of EV-associated RNAs profiled from various normal and cancer cell lines indicate secreted 
RNAs with a size distribution between 25-700 nt  (Pegtel et al. 2010; Noerholm et al. 2012). This 
suggests that most of the RNA transcripts present in these EVs consist of short transcripts. In the 
case of mRNAs, the simplest explanation would be that EVs contain full-length mRNAs that are 
<700 nt, or alternately, are enriched for truncated/fragmented mRNAs. Truncation of mRNAs 
appears to be tightly regulated as recent studies have shown that RNA transcripts can undergo 
widespread post-transcriptional cleavage to produce a range of small coding and noncoding 
RNAs (Mercer et al. 2010). At present, it is unknown whether secreted RNAs are characterized 
by a specific fragmentation or cleavage pattern. 
In certain contexts, EV-associated mRNAs are largely enriched for 3’-UTR fragments 
(Batagov and Kurochkin 2013). This may have important implications in regulating gene 
expression in target cells since the 3’-UTRs of mRNAs are rich in regulatory sequences. As a 
single 3’-UTR contains many miRNA binding sites, transfer of 3’UTR-derived mRNA 
fragments have the potential to directly compete with endogenous miRNAs for the silencing 
machinery, leading to deregulation of mRNAs (Wilczynska and Bushell 2015). Although the 
precise mechanisms for how 3’UTRs are selected for secretion are unknown, one possibility is 
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that mRNAs undergo post-transcriptional cleavage to produce 3’UTR fragments, as reported by 
Mercer et al. (Mercer et al. 2011). Another possibility is that exosome-associated mRNAs 
undergo degradation after secretion via extracellular RNases. This seems unlikely, however, as 
we and others observe sequencing reads spanning both full-length transcripts as well as 
smaller/fragmented transcripts, suggesting that these fragments are generated within the cell 
before sorting into exosomes. 
 
RNA sorting into EVs 
The mechanisms that dictate RNA sorting into EVs is not fully understood, particularly 
for long RNAs. For miRNAs, however, one possibility is through association with AGO 
proteins, a component of the RISC machinery previously found to associate with late endosomes 
(Gibbings et al. 2009). Work done in collaboration with the Weaver lab has shown that Ago2 
sorting into exosomes is regulated by MEK-ERK signaling downstream of activated KRAS 
(McKenzie et al. 2016). In this context, secretion of Ago2 in exosomes was observed in wild 
type KRAS cells (Appendix A.12), but aberrant KRAS signaling prevented Ago2 association 
with MVBs and inclusion into exosomes via phosphorylation on serine-387 (S387) (McKenzie et 
al. 2016). Ago2 depletion in wild type KRAS cells did not affect cellular miRNA levels, but 
levels of exosomal miRNAs were significantly reduced (e.g. let-7a and miR-100)(Appendix 
A.12)(McKenzie et al. 2016). This is consistent with others that report decreased export of EV-
associated miRNAs upon Ago2 knock out(Guduric-Fuchs et al. 2012).  
Despite low levels of exosomal Ago2 secreted by mutant KRAS CRC cells, comparable 
levels of miRNA and other small RNA were observed in mutant KRAS exosomes (Cha et al. 
2015), suggesting Ago2-independent mechanisms are also likely to control sorting of miRNAs. 
Protein alignment of human AGOs indicates serine-387, a phosphorylation site that has been 
shown to affect slicer activity and its localization to P-bodies (Horman et al. 2013; Zeng et al. 
2008), is conserved in Ago-1, -2 and -4, but is absent in Ago3 (Appendix A.13). Interestingly, 
Ago3 is more abundant in mutant KRAS exosomes (Appendix A.13). It is tempting to speculate 
that Ago3 might be resistant to oncogenic signaling and can thus preferentially associate with 
endosomes. Although circulating Ago2 has been abundantly detected in non-vesicular protein 
complexes (Arroyo et al. 2011; Andrey Turchinovich et al. 2011) as well as EVs (Melo et al. 
2014; McKenzie et al. 2016, 2), it remains to be determined whether Ago1, 3 or 4 have roles in 
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exRNA communication. 
In addition to the Ago proteins, other RBPs may regulate exRNA sorting to EVs. For 
example, miR-223-3p was shown to be dependent on Y-Box protein 1 (YBX1) in HEK293T 
cells (Shurtleff et al. 2016). Interestingly, circulating miR-223 is one of the most abundant 
miRNAs associated with HDL in patients with familial hypercholesterolemia(Vickers et al. 
2011). In addition to miRNAs, YBX1 has also been shown to associate with other small RNAs, 
including tRNA fragments and snoRNAs (Goodarzi et al. 2015; Liu et al. 2015, 1), raising the 
possibility that YBX1 contributes to the secretion of various RNA classes. Another mechanism 
may be through sequence-specific motifs that direct RNA trafficking by interaction with specific 
RNA binding proteins. This has been described in T-cells where miRNAs containing the 
‘GGAG’ motif are preferentially sorted to exosomes (Squadrito et al. 2014). Although we and 
others did not find enrichment of sequences containing the ‘GAGG’exo-motif in EVs (Cha et al. 
2015; Shurtleff et al. 2016) , it is likely that sequence-specific export depends on the donor cell, 
or only affects a subpopulation of RNAs. 
Another sorting mechanism may be through post-transcriptional modifications of the 
RNA. It was demonstrated that miRNAs in exosomes were preferentially 3’-uridylated, while 3’-
adenylated miRNA species were mostly cell-enriched (Koppers-Lalic et al. 2014). We also 
observed enrichment of miRNAs containing non-templated A in cellular samples; however, we 
did not detect significanty more 3’-uridylated miRNAs in exosomes (Appendix A.6). 
Interestingly, non-templated terminal nucleotide additions (NTAs) predispose miRNA 
association with RISC (Burroughs et al. 2010), affecting their target effectiveness. Furthermore, 
adenylation and uridylation affect the stability and activity of some miRNAs, and in certain 
context, U-addition is destabilizing (Burroughs et al. 2010). Consistent with this, exRNAs 
reportedly have shorter half-lives (~1.8x shorter) than cellular RNAs (Batagov, Kuznetsov, and 
Kurochkin 2011).  Apart from human and viral miRNAs, adenylation and uridylation can also 
occur at the 3’ ends of yRNA fragments. These uridylated yRNA fragments are also reportedly 
enriched in exosomes(Koppers-Lalic et al. 2014). Exactly how uridylated RNAs are trafficked to 
exosomes is unknown. In mammalian cells, ZCCHC11 (TUT4) and ZCCHC6 (TUT7) mediate 
terminal U-additions to miRNAs (Thornton et al. 2014). One possibility is that these TUTs are 
exported to EVs, although quantitative proteomic analysis argues against the presence of such 
enzymes in exosomes (Exocarta: http://www.exocarta.org/). Another possibility is that 3’ 
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uridylated miRNAs have a higher turnover in cells compared to exosomes. The functional 
significance of 3’-end modifications in secreted RNAs remains to be determined. 
Specific lipids appear to be another important component regulating the sorting of RNA 
into EVs.  It has been shown that miRNAs secreted in exosomes are dependent on hydrolysis of 
sphingomyelin into ceramide by neutral sphingomyelinase 2 (N. Kosaka et al. 2010). Ceramide 
is also abundant in lipid rafts (Hannun and Obeid 2002), and certain RNAs demonstrate 
enhanced affinity to these phospholipid bilayers (Khvorova et al. 1999). It was demonstrated that 
RNAs with a specific secondary structure bind to rafted (liquid-ordered) domains in 
sphingomyelin-cholesterol-phosphatidylcholine vesicles that resemble liquid-ordered lipid phase 
of exosomal membranes (Janas, Janas, and Yarus 2006). Furthermore, posttranscriptional 
changes involving hydrophobic modifications, such as methlation of miR-125b by NSun2, can 
also increase the lipophilicity of RNAs (Hussain et al. 2013). It remains to be determined 
whether the sorting of longer RNA species into EVs are also regulated by lipids. 
 
The physiological role of exRNA 
The functional role of secreted RNAs has been controversial since the first reports of 
exRNA. Although numerous studies have shown that miRNAs can be transferred to neighboring 
cells in experimental settings, evidence demonstrating transfer of miRNAs in biologically 
significant quantities in vivo is lacking. 
Although the number of studies suggesting functional roles for exRNAs in disease as 
well as in normal development is growing, it is not well understood mechanistically how they 
target and function in distant cells in vivo. EV-mediated miRNA transfer between cells has been 
proposed to be a mechanism for intercellular signaling, and EV-associated miRNAs in biofluids 
have been implicated as potential minimally invasive biomarkers for multiple human diseases. 
However, standard preparations of EVs reportedly do not contain many RNA molecules, at least 
this is true of miRNAs (Chevillet et al. 2014). This may require a reevaluation of current models 
suggesting cell-to-cell communication by exRNA. The stoichiometric analysis will be valuable 
for the study of the various classes of RNAs associated with EVs and RNPs, and determining the 
physiologically relevant concentration of exRNAs. In general, long RNAs make up a minority of 
the RNAs secreted in EVs; however, some lncRNAs are suspected to have functional activity at 
low copy numbers (Wilusz, Sunwoo, and Spector 2009).  
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To conclude, there is promising potential for EV-derived exRNAs as disease biomarkers 
and their applications in cancer immunotherapy. However, the mechanisms involved in EV 
secretion and cargo loading, as well as their interaction with target cells is only beginning to 
emerge. It is important to recognize that apart from mRNAs and miRNAs, other RNA classes 
may act as signaling molecules.Essential questions that remain are (2) the major sources of 
various RNAs in bodily fluids, (3) detection and measurement of RNAs in circulation, (4) 
selectivity of export and import, (5) sensitivity and specificity of export to target cells, and (6) 
cell-, tissue-, organ-, and organism-wide impacts of exRNA mediated cell-to-cell 
communication.  
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APPENDIX 
 
 
A 
 
 
Supplemental figures 
 
A.1. 
 
A.1.  Length distribution of small RNA reads to genome.  The small RNA read length 
distribution from serum starved cells and from purified exosomes was determined, as well as the 
5’ nucleotide from each read.  The pattern from total cellular small RNA is consistent with 
primarily miRNA reads, the distribution from exosomes is much broader, encompassing a 
number of small reads derived from many sources (see Figure 1C,D).  Colors represent 
nucleotide identify for the 5’ base, T (cyan), A (red), G (green), and C (blue). 
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A.2. 
 
A.2.  Spearman correlations between miRNA expression profiles in cells and exosomes.  
Pairwise similarity between the RNA sequencing data sets derived from cells and exosomes.  
Spearman correlations are shown between the cell samples (R=0.93-0.96), between exosomes 
and cognate cells (R=0.64-0.83) and between exosome samples (R=0.74-0.86).  Results were 
generated using the DESeq “pooled” method. 
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A.3.
 
 
A.3.  Spearman correlations between miRNA expression profiles in cells and exosomes.  
Similar to Supplemental Figure 2A.  Differential analysis using the DESeq “per condition” 
method. 
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A.4. 
 
A.4.  Spearman correlations between miRNA expression profiles in cells (top) and 
exosomes (bottoms) in reads per million (RPM). 
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A.5. 
 
A.5.  Spearman correlations comparing miRNA expression profiles in exosomes to parent 
cell in RPM. 
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A.6. 
 
A.6. Non-Templated Addition (NTA) of Nucleotides to 3’ Ends of miRNAs. 3’ NTA of A-
tailed miRNAs are enriched in cells independent of KRAS status whereas NTA of C-residues are 
more abundant in wild type KRAS DKs-8 exosomes.  miRNAs with read counts ≥ 500 reads in 
both cells and exosomes were used in the analysis.  Reads mapping to hairpin sequences were 
considered as templated miRNAs (untrimmed).  Reads ≥18 nucleotides that did not map to 
hairpin or genome sequences were trimmed one nucleotide at the 3’-termini and mapped again to 
hairpin sequences.  This was repeated three times to account for NTA’s extending up to three 
nucleotides from the 3’-terminus.  miRNAs significantly enriched in exosomes or cells are 
represented by red and blue circles, respectively. 
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A.7. 
A.7.  Comparison of miRNA 3’ trimming and tailing between cells and exosomes.  Heat 
maps show the extent of either 3’ nucleotide additions (tailing) or 3’ resection (trimming) 
compared to full length miRNA sequences (intact).   
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A.8. 
 
 
 
 
 
 
 
 
 
 
A.8.  MEME analysis of miRNA sequence in exosomes.  MEME analysis was performed to 
attempt to identify sequence motifs that might target miRNAs for export into exosomes.  The top 
most abundant motifs found in miRNAs in Tables 1 and 2 are shown for both cells and exosomes 
from either DKO-1, DKs-8 or DLD-1 cell lines.   
 Top 1 
 sites e-value 
Upregulated in DKO-1 exo 51 1.5e-009 
Upregulated in DKO-1 cell 28 1.5e-007 
Upregulated in DKs-8 exo 22 1.7e-010 
Upregulated in DKs-8 cell 19 7.6e-007 
Upregulated in DLD-1 exo 8 2.3e-003 
Upregulated in DLD-1 cell 23 3.3e-012 
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A.9. 
 
A.9.  miR-100 binding sites in the mTOR 3’UTR.  miR-100 binding sites within the mTOR 
3’UTR.  Mutated nucleotides indicated in red (oligonucleotide sequences in Supplemental Table 
5). 
miRNA  3' guGUUCAAGCCUAGAUGCCCAa 5'
            :|| ||: ||  ||||||| 
Target 5' caTAACTTTAGAAATACGGGTt 3' 284 - 305  160.00  -15.20
  
miRNA  3' guguucaagccuagaUGCCCAa 5'
                         |:|||| 
Target 5' gttgctcctctcaacAT GGGTa 3' 363 - 384  104.00  -6.60
 
miRNA  3' gugUUCAAGCCUA-G-AUGCCCaa 5'
             ||| || |:| | ||: ||  
Target 5' gggAAGGTCTGGTACATATTGGaa 3'  810 - 833  91.00  -7.50
 
Position  Score MFE
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A.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.10.  Presence of mutant DKO-1 donor cells augments miR-100 levels in DKs-8 recipient 
cells.  Taqman qRT-PCR for miR-100.  miR-100 levels increased by approximately 114 copies in 
recipient cells cultured with DKO-1 donor cells pre-treated with control antagomir (AI-CTL) 
compared to recipient cells cultured without donor cells.  Pre-treatment of mutant DKO-1 donor 
cells with miR-100 antagomir inhibitor (AI-100) attenuated this effect.  Absolute levels of miR-
100 determined by standard curve generation of synthetically derived miR-100 (see Methods). 
 
miR-100  
(copies/ng input RNA) 
std dev 
DKO-1 donor AI-100 357.230 16.654 
DKO-1 donor AI-CTL 442.581 12.590 
no donor 329.480 13.615 
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A.11.  
 
 
 
A.11.  Transfer of extracellular miRNAs by mutant DKO-1 cells promotes target 
repression in wild type DKs-8 cells.  Transwell co-culture of DKs-8 recipient cells with or 
without DKs-8 or DKO-1 donor cells.  Luciferase (Luc) expression was measured in DKs-8 
recipient cells expressing Luc fused to three perfectly complementary synthetic miR-222 target 
sites (miR-222-PT) 
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A.12. 
 
 
A.12. Mutant KRAS affects Ago2 secretion in exosomes. A) Representative western blots and 
B) quantification from three independent experiments of equal numbers of exosomes secreted 
from WT (DKs-8) and mutant (DKO-1) cells. Bands normalized to Hsp70. Ago2 depletion by 
shRNAs C)significantly decreases the amount of small RNA in exosomes. D) qRT-PCR of select 
miRNAs from exosomal and cellular RNA isolated from control and Ago2-knock down cells. 
Graph shows fold change compared to shLacZ. Dotted lines indicate no fold change. *p<0.05; 
**p<0.01; ***p<0.001; n.s., not significant. 
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A.13. 
 
 
 
A.13. Differential AGO expression in CRC exosomes compared to cells. A) Representative 
expression levels of AGO1-4 are comparable in total cell lystates (left panel) by western blot 
analysis. AGO2 is enriched in wild-type KRAS (DKs-8) exosomes, while AGO1 and AGO3 
levels are increased in mutant DKO-1 and DLD-1 exosomes (right panel). AGO4 was not 
detected in exosomal lysates. B) Protein sequence alignment of human AGOs at amino acids 
380-395. AGO3 lacks the serine-387 phosphorylation site. 
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